

J. Turgeon, B. Pharm., Ph.D.
C.V. September 2021

CURRICULUM VITAE

Chief Scientific Officer
Tabula Rasa HealthCare (TRHC)
Chief Executive Officer
TRHC Precision Pharmacotherapy Research & Development Institute (PPRDI)
13485 Veteran's Way, Suite 410
Orlando, Florida, 32827
Phone: 856-938-8793

Jacques Turgeon, B.Pharm., Ph.D.
jturgeon@trhc.com

Actual Position

Chief Scientific Officer, Tabula Rasa HealthCare
Chief Executive Officer, TRHC Precision Pharmacotherapy Research & Development
Institute
Professor Emeritus, Faculty of Pharmacy, Université de Montréal

Fellow, Canadian Academy of Health Sciences
Fellow, Académie nationale de Médecine, France

Educational Background

09/1977 - 06/1979	Diploma of Collegiate Studies in Health Sciences, Collège de la Région de l'Amiante, Thetford Mines, Québec.
09/1979 - 05/1983	B.Sc. Pharmacy, École de Pharmacie, Université Laval, Ste-Foy, Québec.
05/1983 - 09/1984	M.Sc., École de Pharmacie, Université Laval, Ste-Foy, Québec.
09/1984 - 12/1987	Ph.D., École de Pharmacie, Université Laval, Ste-Foy, Québec.
01/1988 - 06/1990	Post-doctoral fellowship, Depart of Clinical Pharmacology Vanderbilt University, Nashville, Tennessee

Awards and Distinctions

1980	The Burroughs Wellcome Award; awarded to the student with the highest cumulative average in first year pharmacy.
1981	The Merck Sharp & Dohme Award; awarded to the student with the highest cumulative average in second year Pharmacy.
1981	Medical Research Council of Canada Undergraduate Scholarship.
1982	The Pfizer Award; awarded to the student with the highest cumulative average in third year pharmacy.
1982	Medical Research Council of Canada Undergraduate Research Scholarship.
1982	FRSQ Undergraduate Scholarship.
1983 – 1987	Medical Research Council of Canada Studentship.
1983	The Charles E. Frosst Medal; awarded to the student with the highest cumulative average in the graduating class over a four-year period.
1984	The Smith-Kline & French Undergraduate Research Student Award.
1986	The Pharmaceutical Manufacturers Association of Canada Award.
1987	The Wyeth Award; awarded to a student for excellence in research work.
1987	The Pharmaceutical Manufacturers Association of Canada Award.
01/1988 – 06/1990	Medical Research Council of Canada Fellowship.
07/1990 – 03/1995	Medical Research Council of Canada Scholarship.
1991 – 1992	Prix des Résidents; awarded to a professor at the School of Pharmacy for excellence in post-graduate teaching.
1992	Hoffman LaRoche Award; Canadian Society for Clinical Pharmacology. Awarded to the principal author of the best published article in field of clinical pharmacology in Canada.
1993	UpJohn/AFPC (Association of Faculties of Pharmacy) Young Investigator Award. Awarded in recognition of outstanding research achievement and contribution to pharmacy.
03/1995 – 1995	Scholarship Joseph C. Edwards Foundation Alfred Emile Francoeur Award: awarded to a professor at the School of Pharmacy for excellence in pre-graduate teaching.
1999	Mention spéciale Étudiants en médecine; awarded for excellence in teaching by MD students in medicine.
2000	Alfred Émile Francoeur Award: awarded to a professor at the School of Pharmacy for excellence in pre-graduate teaching.
2006	Pharmacien de coeur et d'action Award: Awarded for research achievement by a reviewer committee from L'Actualité pharmaceutique.

2010	This award is given to a pharmacist whose career exemplifies the values of the Ordre des pharmaciens du Québec: spirit of innovation, commitment to promoting high-quality pharmaceutical care; reputation; personal integrity and ethical standards.
2011	Prix d'excellence en enseignement – Sciences pharmacologiques awarded to a professor by students for excellence in teaching.
2012	Palais des Congrès de Montréal – Ambassador Club – Appointed Ambassador for implication and contribution to the economic development of Montréal.
2013	Prix d'excellence en enseignement – Sciences pharmacologiques awarded to a professor by students for excellence in teaching.
2015	Prix Bâtitseur CRCHUM – décerné par le Centre de recherche du Centre hospitalier de l'Université de Montréal

Research Support

1990 – 1991	Establishment grant; Laval University (\$10 000.00) Investigator: Jacques Turgeon
1990 – 1992	Operating Grant Canadian Heart and Stroke Fondations (Québec): (\$30 000.00). Antiarrhythmic drug effects and toxicity are modulated by drug disposition and metabolism determinants. Principal Investigator: Jacques Turgeon
1990 – 1993	Operating Grant Medical Research Council of Canada: (\$117 079.00). Metabolic and pharmacokinetic interactions involving antiarrhythmic agents. Principal Investigator: Jacques Turgeon Co-investigator: Pierre-Maxime Bélanger
1990 – 1993	Development Grant Medical Research Council of Canada: Operating and Equipment Grant: (\$165 000.00). Modulation of antiarrhythmic drug effects. Principal Investigator: Jacques Turgeon
1990 – 1993	Subvention d'Établissement de Jeune Chercheur du Fonds de la Recherche en Santé du Québec: (\$40 000.00). Modulation of antiarrhythmic drug effects. Principal Investigator: Jacques Turgeon
1990 – 1995	Development Grant Medical Research Council of Canada: Salary: (\$236 064.00). Modulation of antiarrhythmic drug effects. Principal Investigator: Jacques Turgeon

- 1991 – 1993 Operating Grant Canadian Heart and Stroke Fondations (Québec): (\$34 000.00).
Angiotensin Converting Enzyme inhibition and myocardial blood flow regulation.
Principal Investigator: Jacques R. Rouleau
Co-investigator: Jacques Turgeon
- 1992 Quebec Heart Institute Foundation Grant: (\$82 000.00)
Use of the patch-clamp technique to study modulation of cardiac potassium channels by drugs.
Principal investigator: Jacques Turgeon
- 1992 – 1993 Operating Grant Merck / Frosst: (\$60 000.00)
Modulatory effects of ACE inhibitors on myocardial blood flow regulation, ischemia/reperfusion phenomenon and antiarrhythmic drug action.
Co-investigators: John G. Kingma, Jr.
 Jacques R. Rouleau
 Jacques Turgeon
- 1992 – 1994 Operating Grant Canadian Heart and Stroke Fondations (Québec): (\$20 000.00).
Modulators of antiarrhythmic drugs.
Principal Investigator: Jacques Turgeon
- 1993 Quebec Heart Institute Foundation Grant (\$75 000.00)
Use of the double patch-clamp technique to study modulation of cardiac ionic channels and gap junctions.
Principal investigator: Jacques Turgeon
- 1993 – 1995 Operating Grant Canadian Heart and Stroke Fondations (Québec): (\$40 000.00).
Genetically-determined procainamide disposition.
Co-investigators: Pierre-Maxime Bélanger
 Jacques Turgeon
- 1993 – 1996 Operating Grant Medical Research Council of Canada: (\$123 000.00).
Modulation of antiarrhythmic drug effects.
Principal Investigator: Jacques Turgeon
- 1994 Relation between debrisoquine polymorphic drug metabolism and angiotensin converting enzyme inhibitors-induced cough.
Parke-Davis & Hoescht-Roussel: (\$36 000.00)
Co-investigators: Jacques Turgeon and N. Michelle Robitaille

- 1994 Effects of lisinopril on intercellular conductance.
Zeneca Pharma Inc.: (\$15 000.00)
Co-investigators: Jacques Turgeon and Pascal Daleau
- 1994 – 1998 Combined administration of quinidine and propafenone for
atrial fibrillation: the CAQ-PAF study.
Knoll Pharma Inc.: (\$140 000.00)
Co-investigators: Jacques Turgeon
Marcel Gilbert, Gilles O'Hara
- 1994 – 1996 Operating Grant Medical Research Council of Canada:
(\$97 443.00).
Pharmacokinetics and pharmacogenetics of cardiovascular
drugs.
Investigator: Jacques Turgeon
Co-investigators: Gilles O'Hara
Marcel Gilbert
- 1994 – 1997 Operating Grant Canadian Heart and Stroke Fondations
(Québec): (\$30 000.00).
Modulators of Antiarrhythmic drugs.
Investigator: Jacques Turgeon
Co-investigators: Gilles O'Hara
Marcel Gilbert
- 1994 – 1999 Scholarship Joseph C. Edwards Foundation: (\$225 000.00)
Pharmacologie clinique des agents cardiovasculaires
Investigator: Jacques Turgeon
- 1994 Operating Grant Joseph C. Edwards Foundation:
(\$10 000.00)
Pharmacologie clinique des agents cardiovasculaires
Investigator: Jacques Turgeon
- 1995 – 1997 Operating Grant Canadian Heart and Stroke Fondations
(Quebec): (\$20 000.00)
Genetically-determined antihistamine/cardiac drug
interaction.
Investigator: Bettina A. Hamelin
Co-investigator: Jacques Turgeon
- 1995 – 1998 Operating Grant Medical Research Council of Canada:
(\$180 000.00).
Genetic determinants of drug action: histamine receptor
antagonists.
Investigator principal: Bettina A. Hamelin
Co-investigator: Jacques Turgeon

- 1995
Bristol-Myers Squibb Operating Grant (\$40 000.00)
Genotyping of ACE and Angiotensin II receptor polymorphism
Investigator: Jacques Turgeon
Co-investigator: Bettina A. Hamelin
- 1996 – 1999
Operating Grant Medical Research Council of Canada: (\$167 070.00).
Drug actionson repolarization of cardiac ventricular myocytes.
Investigator: Jacques Turgeon
Co-investigators: Bettina A. Hamelin
Gilles O'Hara
Marcel Gilbert
François Philippon
- 1997 – 2000
Operating Grant Canadian Heart and Stroke Fondations (Quebec): (\$48 348.00).
Modulators of antiarrhythmic drug effects.
Investigator: Jacques Turgeon
Co-investigators: Bettina A. Hamelin
Mohamed Chahine
- 1997 – 1998
Quebec Heart Institute Foundation Grant (\$60 000.00).
Effets cardiovasculaires et pharmacocinétique de la venlafaxine.
Investigator : Jacques Turgeon
- 1998
Bristol-Myers Squibb Operating Grant (\$15 000.00)
Polymorphisme génétique et réponse au inhibiteurs de l'enzyme de conversion : Projet CDN-CAP-998.
Investigator : Jacques Turgeon
- 2000 – 2003
Establishment grant (\$300 000)
Université de Montréal
- 2001 –2002
Fonds de Recherche en santé du Québec (\$20 000)
Modulation des effets électrophysiologiques cardiaques par les glycoprotéines P.
Investigator : Jacques Turgeon
- 2002 – 2005
Heart and Stroke foundation of Canada (\$45 000)
Cardiac electrophysiological effects of non-antiarrhythmic drugs: modulatory role of multidrug resistance transporters.
Investigator : Jacques Turgeon

- 2002 – 2003
Fonds de la recherche en santé du Québec (\$81 120)
Valeur prédictive du phénotype du CYP2C9 sur l'établissement d'une dose stable, efficace et sécuritaire de warfarine.
Investigators : Jacques Turgeon, Denis Roy, Gilles O'Hara
- 2002 – 2004
Xanthus Life Sciences (\$247 199.04)
Predictive value of the CYP2C9 phenotype and determination of a stable, effective and safe dose of warfarin: development of a therapeutic nomogram.
Investigators : Jacques Turgeon, Denis Roy, Gilles O'Hara
- 2002 – 2006
Projet structurant VRQ : (\$1 800 000)
Cellule épithéliale de l'intestin: identification de gènes de susceptibilité et de nouvelles cibles thérapeutiques.
Investigator : Émile Levy
Co-investigators (15) : Jacques Turgeon
- 2004 – 2005
Contrat de recherche Écopia (\$50 000)
In vitro characterization of the biotransformation of new Ecopia compounds.
Investigator : Jacques Turgeon
- 2004 – 2007
Subvention de fonctionnement des Instituts canadiens de recherche en santé (\$330 021)
Intersubject variability in drug action: modulatory role of cytochrome P450 isozymes and membrane transporters.
Investigator : Jacques Turgeon
Co-investigators : Lyne Lalonde, Line Labbé, Marie-Claude Vanier
- 2004 – 2007
Subvention de fonctionnement des Instituts de recherche en santé du Canada : Essais contrôlés et randomisés (\$666 750)
The impact of a multidisciplinary, information technology supported program on blood pressure control in primary care.
Investigator : Stéphane Rinfret
Co-investigators (11) : Jacques Turgeon
- 2004 – 2007
Subvention de fonctionnement des Instituts de recherche en santé du Canada (\$133 750)
The impact of a computerised telephone-based reminder and blood pressure monitoring system on medication-taking compliance and blood pressure control in primary care patients with mild to moderate HTA.
Investigator: Pavel Hamet
Co-investigator: Jacques Turgeon

- 2004 – 2007
Pfizer Canada (\$535 000)
The impact of a computerised telephone-based reminder and blood pressure monitoring system on medication-taking compliance and blood pressure control in primary care patients with mild to moderate HTA.
Investigator: Pavel Hamet
Co-investigator: Jacques Turgeon
- 2005 – 2008
Subvention de fonctionnement des Fondations des maladies du coeur du Québec (\$52 500)
Cardiac electrophysiological effects of non-antiarrhythmic drugs : modulatory role of multidrug resistance transporters.
Investigator : Jacques Turgeon
- 2005 – 2009
Subvention de fonctionnement de Génome Canada (\$21.4 millions)
Pharmacogenomics of drug efficacy and toxicity in the treatment of cardiovascular disease.
Investigator : Jean-Claude Tardif
Co-investigators : Michael Murphy
Daniel Gaudet
Guy Rouleau
Jacques Turgeon
- 2006 – 2009
AstraZeneca US (\$1,200,000)
Effects of ACE inhibitors plus high dose CANdesartan on BNP and Inflammation in patients with LV Dysfunction: Impact of renin-angiotensin-aldosterone system genetic polymorphisms – The CANDID-II Trial.
Investigator: Michel White, Simon de Denus
Co-investigators : Jacques Turgeon
- 2006 – 2011
National Institutes of Health (\$1,250,000)
Canadian East-West Heart Failure Network
Investigator: Jean L. Rouleau
Co-investigators : Michel White
Simon De Denus
Jean-Claude Tardif
Jacques Turgeon

2006 – 2010	<p>Canada Foundation for Innovation New Initiatives Fund (13,8 millions \$) Centre de Pharmacogénomique de l'Université de Montréal Investigator : Jean-Claude Tardif Co-investigators : Lambert Busque Marie-Pierre Dubé Pavel Hamet Stanley Nattel Michael Phillips John Rioux Guy Rouleau Daniel Sinnett Jacques Turgeon</p>
2008 – 2010	<p>Heart & Stroke Foundation of Québec (\$60 000) The expression of drug influx/efflux transporters in the heart: a new paradigm for intersubject variability in cardiac drug actions Investigator: Jacques Turgeon</p>
2009 – 2012	<p>Predictors of depression treatment response following an acute coronary syndrome (\$576 426) Investigator: Nancy E. Frasure-Smith Co-investigators: M. Laliberté É. St-André F. Lespérance J. Turgeon A. Nigam, S. Young</p>
2009 – 2012	<p>Pharmacogenetic study of warfarin (\$1 051 841) Investigator : Marie-Pierre Dubé Co-investigators: L. Busque L. Lalonde J. Turgeon R. Côté J. Lelorier J. Ginsberg M. Phillips J. Kassis J.C. Tardif</p>
2010 – 2011	<p>Characterization of novel pathogenic roles of CYP450s in breast cancer (\$100 000) Investigator: Jacques Turgeon Co-investigators: Danuta Balicki Michal Abrahamowicz André Robidoux</p>

- 2012 – 2017
IRSC - The first characterization of functional CYP450s in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drug (\$807 020)
Investigator: Jacques Turgeon
Co-investigators: Véronique Michaud
Benoit Drolet
Chantale Simard
- 2012 – 2015
Fondation des maladies du coeur - The first characterization of functional CYP450s activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs (\$60 000)
Investigator: Jacques Turgeon
Co-investigators: Véronique Michaud
Benoit Drolet
Chantale Simard
- 2013 – 2018
Fondation canadienne pour l'innovation (\$5 780 139)
Integrating metabolomics and interactomics for biomarker and personalized drug discovery in cardiometabolic diseases
Collaborating institutions : Centre hospitalier de l'Université de Montréal (CHUM), Institut de recherches cliniques de Montréal (IRCM), McGill University.
- 2014 – 2018
Ministère des Finances et de l'Économie. Fonds de partenariat pour un Québec innovant. (\$18 374 984)
Optimisation des approches thérapeutiques en soins de première ligne : OPTI-THERA
Co-Investigators: Pavel Hamet, Jacques Turgeon
Co-applicants : Johanne Tremblay
Véronique Michaud
Janusz Kaczorowski
Jean Lachaine
Bartha Knoppers
Lyne, Lalonde
Philippe Awadalla

2017 – Palliative Care Research Consortium and Tabula Rasa
Healthcare Co-sponsorship (\$500 000)
A Prospective Multicenter Cohort Study to Evaluate
the Characteristics and Clinical Implications of
Pharmacogenomic Information Relevant to
Polypharmacy Actions in Patients with Advanced
Illness Who Are Receiving Multiple Drugs for Pain
and Other Disorders.
Co-investigators: Janet Bull
Russell Portenoy
Véronique Michaud
Kevin Bain
Jacques Turgeon

2018 – 2019 Establishment Fund (\$750,000.00)
College of Pharmacy, University of Florida

Professional Experience

05/1983 – 09/1984 Maîtrise ès Sciences Pharmacy
Ecole de Pharmacie, Université Laval
Etudes pharmacocinétiques de la mexiletine chez l'humain.
Director: Odette Grech-Bélanger, Ph.D.

09/1984 – 12/1987 Philosophiae Doctor Pharmacy
Ecole de Pharmacie, Université Laval.
Métabolisme stéréosélectif de la mexiletine: Implication des
isoenzymes du cytochrome P-450.
Director: Odette Grech-Bélanger, Ph.D.

01/1988 – 06/1990 Post-doctoral Fellowship.
Department of Pharmacology, Division of Clinical
Pharmacology, Vanderbilt University.
Pharmacology and pharmacokinetics of antiarrhythmic drugs.
Director: Dan M. Roden, M.D.

01/1988 – 01/1990 Post-doctoral fellow.
Division of Clinical Pharmacology,
Vanderbilt University, School of Medicine.
Nashville, Tennessee.

01/1990 – 06/1990 Research Instructor.
Division of Clinical Pharmacology,
Vanderbilt University, School of Medicine.
Nashville, Tennessee.

06/1990 – 06/1994	Assistant professor, École de pharmacie, Université Laval
07/1994 – 06/1998	Associate professor École de pharmacie, Université Laval
02/1991 – 03/1999	Research director, Quebec Heart Institute Hôpital Laval
06/1997 – 03/1999	Associate professor, Département de Medecine, Faculté de médecine Université Laval
07/1998 – 06/2000	Full professor Faculté de pharmacie, Université Laval
03/1999 – 05/2000	Senior director, Pharmacokinetics Phoenix International Life Sciences
06/2000	Full professor Faculté de pharmacie, Université de Montréal
06/2000 – 05/2005	Dean Faculté de pharmacie, Université de Montréal
06/2005 – 05/2007	Vice-rector — Research Université de Montréal
05/2007 – 06/2014	Director CHUM Research Center
06/2014 – 09/2015	Chief Executive Officer Centre hospitalier de l'Université de Montréal
09/2015 – 12/2017	Chief Scientific Officer Tabula Rasa Healthcare
01/2016 – 12/2017	Dean, Tabula Rasa Healthcare University
06/2016 – 12/2017	Adjunct professor, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania
09/2016 – 12/2017	Adjunct professor, Department of Pharmaceutics, College of Pharmacy, University of Florida
01/2018 – 12/2018	Associate Dean for Lake Nona Campus College of Pharmacy, University of Florida

01/2018 – 12/2018	Professor Department of Pharmaceutics College of Pharmacy, University of Florida
01/2018 – 12/2018	Professor Department of Pharmaceutics College of Pharmacy, University of Florida
01/2019 –	Chief Scientific Officer Tabula Rasa Healthcare Chief Executive Officer Tabula Rasa Healthcare Precision Pharmacotherapy Research & Development Institute

Supervision of Post-doctoral Fellows

10/1991 – 06/1994	Pascal Daleau, Ph.D.
01/1992 – 09/1992	Agnès Coquet, Ph.D.
06/1993 – 06/1994	Christoffe Lefèz, M.D.
07/1998 – 07/1999	Peter Geelen, M.D.
04/2006 – 03/2007	Hakima Yahi-Kerbane, Ph.D.
05/2007 – 01/2008	Heidi Ligeret, Ph.D.
09/2007 – 08/2009	Isabelle Plante, Ph.D.

Supervision of Graduate Students

01/1990 – 05/1993	Luc Poirier, M.Sc. in Pharmacy program
06/1990 – 11/1993	Céline Fiset, Ph.D. in Pharmacy program
09/1990 – 05/1995	Zohreh Abolfathi, Ph.D. in Pharmacy program
09/1991 – 05/1994	Anne Fortin, M.Sc. in Pharmacy program
09/1992 – 05/1994	Sylvain Bussièrès, M.Sc. in Pharmacy program
09/1993 – 08/1995	Line Labbé, M.Sc. in Pharmacy program
01/1994 – 12/1995	Majed Khalifa, M.Sc. in Pharmacy program
09/1994 – 09/1996	Etienne Lessard, M.Sc. in Pharmacy program
09/1995 – 09/1997	Benoit Drolet, M.Sc. in Pharmacy program
09/1995 – 09/1998	Asmaa Bouayad, M.Sc. in Pharmacy program
09/1995 – 05/2000	Line Labbé, Ph.D. in Pharmacy program
01/1996 – 06/1999	Majed Khalifa; Ph.D. in Pharmacy program
09/1996 – 06/2000	Etienne Lessard, Ph.D. in Pharmacy program
09/1997 – 06/2001	Benoit Drolet, Ph.D. in Pharmacy program
09/1997 – 12/2008	Jean Lefebvre, Ph.D. in Pharmacy program
09/1997 – 03/2000	Jimmy Rail, Ph.D. in Pharmacy program
01/1998 – 03/1999	Francis Veillette, M.Sc. in Pharmacy program
09/1998 – 06/2001	Chantale Simard, Ph.D. in Pharmacy program
09/1998 – 03/1999	Dominic Deschênes, MD/M.Sc.
06/2001 – 05/2004	Nour Sharestan, M.Sc. in Pharmacy program
09/2001 – 12/2003	Véronique Michaud, M.Sc. in Pharmacy program
09/2001 – 12/2005	Pierre Morissette, Ph.D. in Pharmacy program
09/2003 – 11/2008	Raymond Hreiche, Ph.D. in Pharmacy program
09/2003 – 03/2008	Lucie Couture, Ph.D. in Pharmacy program
09/2003 – 03/2010	Simon DeDenus, Ph.D. in Pharmacy program
01/2004 – 01/2009	Véronique Michaud, Ph.D. in Pharmacy program
09/2004 – 08/2007	Anna-Maria Chinas, Ph.D. in Pharmacy program
09/2004 – 04/2009	Julie Grenier, Ph.D. in Pharmacy program
09/2004 – 11/2009	Frédérique Fenneteau, Ph.D. in Pharmacy program
10/2004 – 05/2012	Marcin Zakrzewski, Ph.D. in Pharmacy program
05/2007 – 09/2008	Ève Tonietto, M.Sc. in Hospital Pharmacy
05/2007 – 09/2008	Sophie Cuerrier, M.Sc. in Hospital Pharmacy
05/2007 – 09/2008	Marianne Boyer, M.Sc. in Hospital Pharmacy
01/2007 – 09/2009	Tatiana Martynova, M.Sc. in Pharmacy program
05/2007 – 03/2009	MarieLorkipanidzé, Ph.D. in Pharmacy program
01/2007 – 05/2012	Philippe Colucci, Ph.D. in Pharmacy program
09/2007 – 12/2011	Andréa Sirhan-Daneau, M.Sc. in Pharmacy program

05/2008 – 09/2009	Philippe Bouchard, M.Sc in Hospital Pharmacy
05/2008 – 09/2009	Sarah Bilodeau, M.Sc in Hospital Pharmacy
05/2008 – 09/2009	Karine Alain, M.Sc in Hospital Pharmacy
05/2009 – 09/2010	Audrey Buisson, M.Sc in Hospital Pharmacy
05/2009 – 09/2010	France Dion, M.Sc in Hospital Pharmacy
05/2009 – 09/2010	Anne-Geneviève Genest, M.Sc in Hospital Pharmacy
05/2009 – 09/2010	Robert Johns, M.Sc in Hospital Pharmacy
05/2009 – 09/2010	Marie-Perre Nolet, M.Sc in Hospital Pharmacy
01/2010 – 11/2011	Catherine Armstrong, M.Sc. in Pharmaceutical Sciences
05/2010 – 06/2016	Jade Hugué, Ph.D. in Pharmacy Program
11/2010 – 06/2017	Jennifer Lu, Ph.D. in Pharmacy Program
01/2011 – 12/2012	Yat Hei Leung, M. Sc. in Pharmaceutical Sciences
05/2011 – 09/2012	Maude Beauchamp-Vien, M.Sc in Hospital Pharmacy
05/2011 – 09/2012	Émilie Boisvert, M.Sc in Hospital Pharmacy
05/2011 – 09/2012	Ann-Sophie Payette, M.Sc in Hospital Pharmacy
05/2011 – 09/2012	Alessandra Stortini, M.Sc in Hospital Pharmacy
05/2012 – 09/2013	Benoît Crevier, M.Sc in Hospital Pharmacy
05/2012 – 09/2013	Suhail Jiouni Sami, M.Sc in Hospital Pharmacy
05/2012 – 09/2013	Jennifer Yee, M.Sc in Hospital Pharmacy
09/2012 – 06/2014	Yoanna Skrobik, M.Sc. in Pharmaceutical Sciences
01/2013 – 12/2017	Yat Hei Leung, Ph.D. in Pharmaceutical Sciences
09/2013 – 09/2014	Parisa Karimi, M.Sc. in Pharmaceutical Sciences, co-direction
09/2013 – 09/2014	Parastoo Karimi, M.Sc. in Pharmaceutical Sciences, co-direction
09/2013 – 08/2014	Sophie Gravel, M.Sc. in Pharmaceutical Sciences, co-direction
08/2014 –	Sophie Gravel, Ph.D. in Pharmaceutical Sciences, co-direction
01/2015 – 05/2017	Alexia Grangeon, Ph.D. in Pharmaceutical Sciences, co-direction

Educational Involvement

1984	President of the First Annual Québec Student Research Meeting, Ste-Foy, Québec.
1984 – 1986	Graduate Students in Pharmacy delegate at l'Union des Gradués Inscrits à Laval (UGIL).
1984 – 1987	Member, Graduate Programme Committee, Ecole de Pharmacie, Université Laval.
1985 – 1987	Member, Bureau of Direction, Ecole de Pharmacie, Université Laval.
1986	President of the Third Annual Quebec Student Research Meeting, Ste-Foy, Quebec.
	1987, 1990 - 1999 Member, Research Committee, School of Pharmacy, University Laval.
1990 – 1999	Member, Quebec Heart Institute
1990 – 1999	Member, Department of pharmacy, Laval Hospital
1991 – 1994	Member, Junior Personnel Committee, Heart & Stroke Foundation Canada
1991 – 1999	Member, Scientific Committee, Heart & Stroke Foundation Quebec.
1991 – 1999	Research director, Quebec Heart Institute
1991 – 1999	Member, research Committee, Laval Hospital

1991 – 1999	Member, CMDP, Laval Hospital
1992 – 1999	Vice-chair, Basic Research Committee, Laval Hospital
1993 – 1996	Member, Grant Review Committee, Cardiovascular A, Medical Research Council of Canada
1994 – 1995	Member, Grant Review Committee II, Heart and Stroke Foundation of Canada
1995 – 1999	Deputy Chair, Grant Review Committee III, Heart and Stroke Foundation of Canada
1994 – 1998	Member, FRSQ/CCP committee
1994 – 1997	Director, Arrhythmia section, FRSQ Cardiovascular Network
1995 – 1998	Research director, École de pharmacie, Université Laval
1995 – 2001	Conseiller, Club de recherches cliniques du Québec
1997 – 1999	Director, FRSQ Cardiovascular Network
1998 – 2000	Member, FRSQ Senior scholarship committee
2002 – 2003	President, Club de recherches cliniques du Québec
2000 – 2006	Member, Prix Galien
2000 – 2006	President, Belleau-Nickerson Award
2000 – 2006	Member, Scientific Committee Rx&D Foundation
2001 – 2002	Vice-President, Club de recherches cliniques du Québec
2002 – 2003	Member, Committee IV, Heart and Stroke Foundation
2002 – 2005	Member, Board of Directors, Montreal Heart Institute
2002 – 2005	Member, Board of Directors, Hôpital du Sacré-Coeur de Montréal
2002 – 2005	Vice-President, Board of Directors, Fondation de l'Hôpital du Sacré-Coeur de Montréal
2003 – 2004	Outgoing President, Club de recherches cliniques du Québec
2003 – 2006	Member, Comité Sciences pharmaceutiques, CIHR
2005 – 2007	Member, Board of Directors, Centre hospitalier de l'Université de Montréal.
2005 – 2007	Meeting Participation, Board of Directors, Université de Montréal.
2005 – 2007	Meeting Participation, Comité de la planification, Université de Montréal.
2005 – 2007	Meeting Participation, Comité exécutif, Université de Montréal.
2005 – 2007	President, Comité d'étude et d'administration de la recherche, Université de Montréal.
2005 – 2007	President, Table des vice-doyens à la recherche, Université de Montréal.
2005 – 2007	Président et membre d'office du Comité d'attribution du fonds Georg Stellari.
2005 – 2007	President and member, Comité de la radioprotection, Université de Montréal.
2005 – 2007	Member, Asemblée universitaire, Université de Montréal.
2005 – 2007	Member, Comité de la recherche, Université de Montréal.
2005 – 2007	Member, Comité ad hoc sur la gestion des partenariats Université – bailleurs de fonds, Université de Montréal.
2005 – 2007	Member, Comité des prix et distinctions, Université de Montréal.
2005 – 2012	Board Member, Canadian Academy of Health Sciences.

2006 – 2007	Member, Conseil d'administration, Centre québécois d'innovation en biotechnologie.
2006 – 2007	Member, Conseil d'administration, Agence de la Santé et des Services sociaux de Montréal.
2006 – 2015	Member, Conseil d'administration, Laboratoire Médical Biron.
2006 – 2007	Member, Conseil d'administration, Technopôle Angus.
2007 – 2015	Member, Conseil consultatif du CHUM
2007 – 2015	Member, Table des chefs de département du CHUM.
2007 – 2015	Member, Conseil d'administration de la Fondation du CHUM
2007 – 2015	Member, Conseil des médecins, dentistes et pharmaciens du CHUM
2007 – 2015	Member, Comité conseil de la recherche de l'Université de Montréal
2008 – 2015	Member, Comité de coordination du CHUM
2008 – 2013	Vice-president, ASCPT, Pharmacogenetics and Molecular Pharmacology Section
2008 – 2015	Member, Comité stratégique du Club des Ambassadeurs, Palais des Congrès de Montréal
2009 – 2015	Member accrédité, Département de pharmacologie, Université de Montréal
2014 – 2015	Membre du Comité consultatif externe du Regroupement en soins de santé personnalisés au Québec (RSSPQ)
2018 –	Member, Lake Nona Medical City Research Council
2018 –	Member, Lake Nona Medical City Executive Council
2018 – 2019	Member, College of Pharmacy Research Committee, University of Florida
2018 – 2019	Member, Associate deans for Research Committee, University of Florida
2018 – 2019	Member, Executive Committee College of Pharmacy, University of Florida
2019 –	Treasurer, American Society for Clinical Pharmacology

Professional Societies

Ordre des Pharmaciens du Québec (No 85249)
 Association of Faculties of Pharmacy of Canada
 American Society for Clinical Pharmacology and Therapeutics
 American Heart Association
 American Federation for Clinical Research
 The International Society for the Study of Xenobiotics
 Canadian Society for Clinical Research
 Canadian Society for Clinical Pharmacology
 Club de Recherches Cliniques du Québec
 Société de Cardiologie de Québec
 Canadian Academy of Health Sciences
 Canadian Diabetes Association
 Académie nationale de médecine, France

Publications

A) Original Manuscripts:

1. Grech-Bélanger, O., Turgeon, J., Gilbert, M. **High Pressure Liquid Chromatographic Assay for Mexiletine in Serum.** J. Chromatogr. Sci., 1984; 22:490-492.
2. Turgeon, J. (1984). **Etudes pharmacocinétiques de la mexiletine chez l'humain.** Thèse de Maîtrise ès Sciences (no: 6192), École des gradués, Université Laval, Ste-Foy, Québec.
3. Grech-Bélanger, O., Turgeon, J., Gilbert, M. **High Performance Liquid Chromatographic Assay for Mexiletine Enantiomers in Human Plasma.** J. Chromatogr., 1985; 337:172-177.
4. Grech-Bélanger, O. Gilbert, M., Turgeon, J., LeBlanc, P.P. **Effect of Cigarette Smoking on Mexiletine Kinetics.** Clin. Pharmacol. Ther., 1985; 37:638-643.
5. Grech-Bélanger, O., Turgeon, J., Gilbert, M. **Stereoselective Disposition of Mexiletine in Man.** Br. J. Clin. Pharmac., 1986; 21:481-497.
6. Turgeon, J., Grech-Bélanger, O., Gilbert, M. **Erythrocytes and Serum Distribution of Mexiletine in Man.** Biopharmaceutics and Drug Disposition, 1987; 8: 571-576.
7. Grech-Bélanger, O., Turgeon, J., Lalande, M. **2,6-Dimethylphenol: A New Metabolite of Mexiletine.** Res. Commun. Chem. Pathol. Pharmacol., 1987; 58:53-62.
8. Turgeon, J. (1987). **Métabolisme stéréosélectif de la mexiletine: Implication des isoenzymes du cytochrome P-450.** Thèse de Doctorat. École des gradués, Université Laval, Ste-Foy, Québec.
9. Turgeon, J., Funck-Brentano, C., Gray, H.T., Roden, D.M. **An Improved High-Performance Liquid Chromatographic Assay for Encainide and Its Metabolites in Human Body Fluids.** J. Chromatogr., 1989; 490: 165-174.
10. Funck-Brentano, C., Turgeon, J., Woosley, R.L., Roden, D.M. **Effect of Low Dose Quinidine on Encainide Pharmacokinetics and Pharmacodynamics: Influence of Genetic Polymorphism.** J. Pharmacol. Exp. Ther., 1989; 249:134-142.
11. Turgeon, J., Roden, D.M. **Pharmacokinetic Profile of Encainide.** Clin. Pharmacol. Ther., 1989; 45:692-694.
12. Kroemer, H.K., Turgeon, J., Parker R.A., Roden, D.M. **Flecainide Enantiomers: Disposition in Man and Electrophysiologic Action *In Vitro*.** Clin Pharmacol. Ther., 1989; 46:584-590.
13. Turgeon, J., Kroemer, H.K., Prakash, C., Blair, I., Roden, D.M. **Stereoselective Determination of Flecainide in Human Plasma by HPLC with Fluorescence Detection.** J. Pharm. Sci., 1990; 79:91-95.
14. Turgeon, J., Pavlou H.N., Wong, W., Funck-Brentano, C., Roden, D.M. **Genetically-Determined Encainide-Quinidine Interaction at Steady-State in Patients with Arrhythmias.** J. Pharmacol. Exp. Ther., 1990; 255:642-649.
15. Turgeon, J., Murray K.T., Roden, D.M. **Effects of Drug Metabolism, Metabolites and Stereoselectivity on Antiarrhythmic Drug Action.** J. Cardiovasc. Electrophysiol., 1990; 1:238-260.

16. Grech-Bélanger, O., Turgeon, J., Lalande M., Bélanger, P.M. **Meta-Hydroxymexiletine - A New Metabolite of Mexiletine: Isolation, Characterization and Species Differences in its Formation.** Drug Metab. Disp., 1991; 19:458-461.
17. Dasgupta A, Rosenzweig IB, Turgeon J., Raisys VA. **Encainide and Metabolites Analysis in Serum or Plasma Using a Reversed-Phase High-Performance Liquid Chromatographic Technique.** J Chromatogr. 1990 Mar 16;526(1):260-5.
18. Turgeon, J., Evans W.E., Relling, M.V., Wilkinson, G.R., Roden, D.M. **Phenotypic Debrisoquine 4-Hydroxylase Activity among Extensive Metabolizers Appears Unrelated to Genotype.** Br. J. Clin. Pharmacol., 1991; 32:283-288.
19. Turgeon, J., Funck-Brentano, C., Gray, H.T., Pavlou, H.N., Prakash, C., Blair, I.A., Roden, D.M. **Genetically-Determined Stereoselective Excretion of Encainide and its Metabolites in Humans and Electrophysiological Effects of its Enantiomers in Canine Cardiac Purkinje Fibers.** Clin. Pharmacol. Ther., 1991; 49:488-496.
20. Turgeon, J., Uprichard, A.C.G., Bélanger, P.M., Harron, D.W.G., Grech-Bélanger, O. **Resolution and Electrophysiological Effects of Mexiletine Enantiomers.** J. Pharm. Pharmacol., 1991; 43:630-635.
21. Turgeon, J., Fiset, C., Giguère, R., Gilbert, M., Moerike, K., Rouleau, J.R., Kroemer, H.K., Eichelbaum, M., Grech-Bélanger, O., Bélanger, P.M. **Influence of Debrisoquine Phenotype and of Quinidine on Mexiletine Disposition.** J. Pharmacol. Exp. Ther., 1991; 259:789-798.
22. Birgersdotter, U.M., Wong, W., Turgeon, J., Roden, D.M. **Stereoselective Genetically-Determined Interaction Between Chronic Flecainide and Quinidine in Patients with Arrhythmias.** Br. J. Clin. Pharmacol., 1992; 33:275-280.
23. Turgeon, J., Wisialowski, T.A., Wong, W., Altemeier, W.A., Wikswo, J.P. Jr., Roden, D.M. **Suppression of Longitudinal Versus Transverse Conduction by Sodium Channel Block: Effects of Sodium Bolus.** Circulation, 1992; 85:2221-2226.
24. Turgeon, J., Paré, J.R.J., Lalande, M., Grech-Bélanger, O., Bélanger, P.M. **Isolation and Characterization by Spectroscopic Methods of Two Glucuronide Metabolites after N-Oxidation and Deamination.** Drug Metab. Disp., 1992; 20:762-769.
25. Abolfathi, Z., Bélanger, P.M., Gilbert, M., Rouleau, J.R., Turgeon, J. **Improved High Performance Liquid Chromatographic Assay for the Stereoselective Disposition of Mexiletine.** J. Chromatogr., 1992; 579:366-370.
26. Turgeon, J., Bélanger, P.M., Paré, J.R.J. **On the Structure of Primary Alkylamine Acid-Labile Conjugates.** Spectroscopy an International Journal, 1992; 10:39-41.
27. Fiset, C., Philippon, F., Gilbert, M., Turgeon, J. **Stereoselective High Performance Liquid Chromatographic Assay for Determination of Sotalol Enantiomers in Biological Fluids.** J. Chromatogr., 1993; 612:231-237.
28. Fiset, C., Philippon, F., Gilbert, M., Turgeon, J. **Stereoselective Disposition of (±)-Sotalol at Steady-State Sonditions.** Br. J. Clin. Pharmacol., 1993; 36:75-77.
29. Abolfathi, Z., Fiset, C., Gilbert, M., Kroemer, H., Bélanger, P.M., Turgeon, J. **Role of Polymorphic Debrisoquine 4-Hydroxylase Activity in the Stereoslective Disposition of Mexiletine in Human.** J. Pharmacol. Exp. Ther., 1993; 266:1196-1201.

30. Daleau, P., Turgeon, J. **Inhibition of the Delayed Rectifier K⁺ Current by Triamterene in Guinea Pig Ventricular Myocytes.** *Circ. Res.*, 1994; 74:1114-1120.
31. Daleau, P., Turgeon, J. **Angiotensin II Modulates the Delayed Rectifier Potassium Current of Guinea Pig Ventricular Myocytes.** *Pflügers Arch.*, 1994; 427:553-555.
32. Turgeon, J., Daleau, P., Bennett, P.B., Wiggins, S.S., Selby, L., Roden, D.M. **Block of I_{Ks}, the Slow Component of the Delayed Rectifier K⁺ Current, by the Diuretic Agent Indapamide in Guinea Pig Ventricular Myocytes.** *Circ. Res.*, 1994; 75:879-886.
33. Daleau, P., Lessard, E., Groleau, M.F., Turgeon, J. **Erythromycin Blocks the Rapid Component of the Delayed Rectifier Potassium Current and Lengthens Repolarization of Guinea Pig Ventricular Myocytes.** *Circulation*, 1995; 91:3010-3016.
34. Turgeon, J., Fiset, C., Kingma, M.L., Lacoursière, L., Kingma, J.G.Jr. **Influence of Indapamide and Chlorthalidone on Reperfusion-Induced Arrhythmias in Isolated Guinea Pig Hearts.** *J Cardiovasc. Pharmacol.*, 1995, 36:518-523.
34. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **The Disposition of Fluoxetine but not Sertraline is Altered in Poor Metabolizers of Debrisoquine.** *Clin Pharmacol Ther.*, 1996; 60:512-521.
35. Daleau, P., Khalifa, M., Turgeon, J. **Effects of Cadmium and Nisoldipine on the Delayed Rectifier Potassium Current in Guinea Pig Ventricular Myocytes.** *J. Pharmacol. Exp. Ther.*, 1997; 281:828-831.
36. Daleau, P., Turgeon, J. **Effects of Lisinopril on Intercellular Resistance of Guinea Pig Ventricular Myocytes.** *Can. J. Physiol. Pharmacol.*, 1997; 75:363-367.
37. Lessard, E., Fortin, A., Bélanger, P.M., Beaune, P., Hamelin, B.A., Turgeon, J. **Role of CYP2D6 in the N-Hydroxylation of Procainamide.** *Pharmacogenetics* 1997; 7:381-390.
38. Fiset, J., Hamelin, B.A., Turgeon, J. **Block of I_{Ks} by the Diuretic agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug *dl*-Sotalol.** *J. Pharmacol. Exp. Ther.*, 1997; 283:148-156.
39. Lessard, E., Fortin, A., Coquet, A., Bélanger, P.M., Hamelin, B.A., Turgeon, J. **Improved High Performance Liquid Chromatographic Assay for the Determination of Procainamide and its N-Acetylated Metabolite in Plasma.** *J. Chromatogr. Sci.*, 1998; 36:49-54.
40. Drolet, B., Khalifa, M., Daleau, P., Hamelin, B.A., Turgeon, J. **Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval.** *Circulation*, 1998; 97:204-210.
41. Turgeon, J. **Pharmacokinetics of Angiotensin II Type I Receptor Antagonists: Focus on Losartan, Candesartan and Valsartan.** *Can. J. Clin. Pharmacol.*, 1998; 5:14-22.
42. Hamelin, B.A., Turgeon, J. **Hydrophilicity/Lipophilicity: Relevance for the Pharmacology and Clinical Effects of HMG-CoA Reductase Inhibitors.** *Trends in Pharmacological Sciences (TIPS)* 1998; 19:26-37.
43. Hamelin, B.A., Bouayad, A., Drolet, B., Gravel A., Turgeon, J. **In Vitro Characterization of CYP2D6 Inhibition by Classic Histamine H₁ Receptor Antagonists.** *Drug Metab. Disp.*, 1998; 26:536-539.

44. Bogaty, P., Robitaille, N.M., Solymoss, S., Auger, D., Boyer, L., Labbé, L., Simard, S., Genest, J.Jr., Turgeon, J. **Atherogenic, Hemostatic and other Potential Risk Markers in Subjects with Previous Isolated Myocardial Infarction Compared to Longstanding Uncomplicated Stable Angina : the Random Hypothesis Revisited.** *Am. Heart J.*, 1998; 136:884-893.
45. Khalifa, M., Drolet, B., Daleau, P., Lefez, C., Gilbert, M., Plante, S., O'Hara, G., Gleeton, O., Hamelin, B.A., Turgeon, J. **Block of Potassium Currents in Guinea Pig Ventricular Myocytes and Lengthening of Cardiac Repolarization in Man by the Histamine H1 Receptor Antagonist Diphenhydramine.** *J. Pharmacol. Exp. Ther.*, 1999; 288:858-865.
46. Labbé, L., Abolfathi, Z., Robitaille, N.M., St-Maurice, F., Gilbert, M., Turgeon, J. **Stereoselective Disposition of Mexiletine During the Concomitant Administration of Caffeine in Man.** *Ther. Drug Monitor.*, 1999; 21:191-199.
47. Drolet, B., Vincent, F., Rail, J., Chahine, M., Deschênes, D., Nadeau, S., Khalifa, M., Hamelin, B.A., Turgeon, J. **Thioridazine Lengthens Repolarization of Cardiac Ventricular Myocytes by Block of the Delayed Rectifier Potassium Current.** *J. Pharmacol. Exp. Ther.*, 1999; 288:1261-1268.
48. Lessard, E., Yessine, MA., Hamelin, B., O'Hara, G., LeBlanc J., Turgeon, J. **Influence of CYP2D6 Activity on the Disposition of the Antidepressant Agent Venlafaxine in Human.** *Pharmacogenetics*, 1999; 9:435-443.
49. Geelen, P., O'Hara, G.E., Roy, N., Talajic, M., Roy, D., Plante, S., Turgeon, J. **Comparison of Propafenone Versus Procainamide for the Acute Treatment of Atrial Fibrillation after Cardiac Surgery.** *Am. J. Cardiol.*, 1999; 84:345-347.
50. Geelen, P., Drolet, B., Lessard, E, Gilbert, P., O'Hara, G., Turgeon, J. **Concomitant Block of the Rapid (I_{Kr}) and Slow (I_{Ks}) Components of the Delayed Rectifier Potassium Current is Associated with Potentiation of Drug Effects on Lengthening of Cardiac Repolarization.** *J. Cardiovasc. Pharmacol. Exp. Ther.*, 1999; 4:143-150.
51. Hamelin, BA, Dorson, PG, Pabis, D., Still, D., Bouchard, RH, Pourcher, E., Rail, J., Turgeon, J., Crismon, ML. **CYP2D6 Mutations and Therapeutic Outcome in Schizophrenic Patients.** *Pharmacotherapy*, 1999; 19:1057-1063.
52. Khalifa, M., Daleau, P., Turgeon, J. **Mechanism of Sodium Channel Block by Venlafaxine in Guinea Pig Ventricular Myocytes.** *J. Pharmacol. Exp. Ther.*, 1999; 291:280-284.
53. Labbé L., Turgeon, J. **Clinical Pharmacokinetics of Mexiletine.** *Clinical Pharmacokinetics*, 1999; 37:361-384.
54. Lessard, E., Hamelin, BA, Labbé, L., Ohara, G., Bélanger, P.M., Turgeon, J. **Involvement of CYP2D6 Activity in the N-Oxidation of Procainamide in Man.** *Pharmacogenetics*, 1999; 9:683-696.
55. Drolet, B., Zhang, S., Deschênes, D., Rail, J., Nadeau, S., Zhou, Z., January, C.T., Turgeon, J. **Droperidol Lengthens Cardiac Repolarization Due to Block of the Rapid Component of the Delayed Rectifier Potassium Current.** *J. Cardiovasc. Electrophysiol.*, 1999; 10:1597-1604.
56. Hamelin, B.A., Bouayad, A., Methot, J., Jobin, J., Desgagnés, P., Poirier, P., Allaire, J., Dumesnil, J., Turgeon, J. **Significant Interaction Between the Nonprescription Antihistamine Diphenhydramine and the CYP2D6 Substrate Metoprolol in Healthy Men with High or Low CYP2D6 Activity.** *Clin Pharmacol. Ther.*, 2000; 67:466-467.

57. Geelen, P., O'Hara, G.E., Plante, S., Philippon, F., Gilbert, M., Turgeon, J. **Ischemia-Induced Action Potential Shortening is Blunted by D-Sotalol in a Pig Model of Reversible Myocardial Ischemia.** *J. Cardiovasc. Pharmacol.*, 2000; 35:638-645.
58. Geelen, P., Drolet, B., Rail, J., Bérubé, J., Daleau, P., Rousseau, G., Cardinal, R., O'Hara, G.E., Turgeon, J. **Sildenafil (Viagra®) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current.** *Circulation*, 2000; 102:275-277.
59. Labbé, L., Sirois, C., Pilote, S., Arseneault, M., Robitaille, N.M., Turgeon, J., Hamelin, B.A. **Effect of Gender, Sex Hormones, Time Variables and Physiologic Urinary pH on Apparent CYP2D6 Activity as Assessed by Metabolic Ratios of Marker Substrates.** *Pharmacogenetics*, 2000; 10:425-438.
60. Labbé, L., O'Hara, G.E., Lefebvre, M., Lessard, E., Gilbert, M., Adedoyen, A., Champagne, J., Hamelin, B.A., Turgeon, J. **Pharmacokinetic and Pharmacodynamic Interaction Between Mexiletine and Propafenone in Man.** *Clin. Pharmacol. Ther.*, 2000; 67:44-57.
61. Drolet, B., Emond, A., Fortin, V., Daleau, P., Rousseau, G., Cardinal, R., Turgeon, J. **Vitamin K Modulates Cardiac Action Potential by Blocking Sodium and Potassium Ion Channels.** *J. Cardiovasc. Pharmacol. Therapeut.*, 2000; 5:267-273.
62. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Turgeon, J. **Domperidone (Motilium) Should Not Be Considered as a No Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders.** *Circulation*, 2000; 102:1883-1885.
63. Lessard, E., Yessine, M.A., Hamelin, B., O'Hara, G., LeBlanc J., Turgeon, J. **Venlafaxine-Diphenhydramine Interaction in Human Due to CYP2D6 Inhibition.** *J. Clin. Psychopharmacol.*, 2001; 21:175-184.
64. D'Angelo, G., Potvin, D., Turgeon, J. **Carry-Over Effects in Bioequivalence Studies.** *J. Biopharm. Stat.*, 2001;11:35-43.
65. Simard, C., O'Hara, G.E., Prévost, J., Guilbaud, R., Massé, R., Turgeon, J. **Study of the Drug-Drug Interaction Between Simvastatin and Cisapride in Man.** *Eur. J. Clin. Pharmacol.*, 2001;57:229-234.
66. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Simard, C., Turgeon, J. **Pimozide (Orap®) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current in Native Cardiac Myocytes.** *J. Cardiovasc. Pharmacol. Ther.*, 2001;6:255-260.
67. Dumesnil, J.G., Turgeon, J., Tremblay, A., Poirier, P., Gilbert, M., Gagnon, L., St-Pierre, S., Garneau, C., Lemieux, I., Pascot, A., Bergeron, J., Després, J.P. **Effect of Low-Glycaemic – Low Fat- High Protein Diet on the Atherogenic Metabolic Risk Profile of Abdominally Obese Men.** *Br J Nutr* 2001;86:557-568.
68. Labbé, L., Abolfathi, Z., Lessard, E., Packdeel, H., Beaune, P., Turgeon, J. **Role of Specific Cytochrome P450 Isozymes in the N-Oxidation of the Antiarrhythmic Agent Mexiletine.** *Xenobiotica* 2003; 33 :13-25.
69. Eap, C., Lessard, E., Yessine, M.A., O'Hara, G.E., Brawand-Amey, M., Baumann, P., Turgeon, J. **Role of CYP2D6 in the Stereoselective Disposition of Venlafaxine in Humans.** *Pharmacogenetics* 2003;13:39-47.

70. Drolet, B.k Yang, T., Daleau, P., Roden, D.M., Turgeon, J. **Risperidone Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current.** J Cardiovascular Pharmacology 2003;41:934-937.
71. Simard, C., Turgeon, J. **The Pharmacokinetics of Ezetimibe.** Can J Clinical Pharmacology; 2003;10(suppl. A):13A-20A.
72. Haller-Gloor, F., Chin B. Eap, Turgeon, J., Baumann, P. **High-Dose Venlafaxine Treatment in a Depressive Patient with a Genetic CYP2D6 Deficiency.** International Journal of Psychiatry in Clinical Practice; 2004;8:1-5.
73. Labbé, L., Robitaille, N.M., Lefez, C., Potvin, D., Gilbert, M., O'Hara, G., Turgeon, J. **Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man.** Ther Drug Monitoring, 2004;26:492-498.
74. Simard, C., Michaud, V., Gibbs, B., Massé, R., Lessard, E., Turgeon, J. **Identification of the cytochrome P450 enzymes involved in the metabolism of dompéridone.** Xenobiotica, 2004;34(11/12):1013-1023.
75. Morissette, P., Hreiche R., Turgeon, J. **Drug-induced long QT syndrome and torsade de pointes.** Can J Cardiol, 2005;21(10):857-864.
76. Couture, L., Nash, J., Turgeon, J. **The ATP-Binding Cassette (ABC) Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.** Pharmacol Rev, 2006;58:244-258.
77. Turgeon, J., Pharand, C., Michaud V. **Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.** *Commentary*, Canadian Medical Association Journal 2006; 174(12)1729-30.
78. Michaud, V., Mouksassi, M-S, Labbé, L., Bélanger, P-M, Ayotte-Ferron, L., Gilbert, M., Grech-Bélanger, O., J. Turgeon. **Inhibitory effects of propafenone on the pharmacokinetics of caffeine in man.** Therapeutics Drug Monitoring, 2006 Dec;28(6) :779-83.
79. Morissette, P., Hreiche, R., Turgeon, J. **Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.** Can J Physiol Pharmacol, 2006;84:1285-1290.
80. Lefebvre, J., Poirier, L., Poirier, P., Turgeon, J., Y. Lacourcière. **The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.** Br J Clin Pharmacol, 2006;63:5;575-582.
81. Michaud, V., Simard, C., Turgeon, J. **An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies.** J Chromatogr B, 2007;852:611-616.
82. Lordkipanidzé, M., Pharand, C., Schampaert, E., Turgeon, J., Palisaitis, D.A., Diodati, J.G. **A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.** Eur Heart J 2007;28:1702-8.
83. Couture, L., Nash, J.A., Turgeon, J. **Role of ABC (ATP-Binding Cassette) Transporters in Drug Distribution to the Heart and Protection from Toxic Compounds.** Heart Metab J, 2007;35:16-21.

84. Morissette, P., Hreiche, R., Vo, D., Knaus, E.E., J. Turgeon. **Olanzapine (Zyprexa) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.** J Psychopharmacol, 2007;Sept;21(7):735-41.
85. Zakrzewski-Jakubiak, M., de Denus, S., Dubé, M.-P., Bélanger, F., White, M., Turgeon, J. **Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure.** Br J Clin Pharmacol, 2008;65:5;742-751.
86. Michaud, V., Vanier, M.C., Brouillette, D., Roy, D., Verret, L., Noel, N., Taillon, I., O'Hara, G., Gossard, D., Champagne, M., Goodman, K., Renaud, Y., Brown, A., Phillips, M., Ajami, A.M., Turgeon, J. **Combinaison of Phenotype Assessments and CYP2C9-VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients.** Clin Pharmacol Ther, 2008;83(5):740-748.
87. Hreiche, R., Morissette, P., Turgeon, J. **Drug-induced Long QT Syndrome in women: Review of current evidence and remaining gaps.** Gender Medicine, 2008(5)2:124-35.
88. de Denus, S., Zakrzewski-Jakubiak, M., Dubé, M.P., Bélanger, F., Lepage, S., Leblanc, M.H., Gossard, D., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Touyz, R., Turgeon, J., White, M. **Effects of AGTR1 A1166C gene polymorphism in patients heart failure treated with Candesartan.** Ann Pharmacother, 2008(42):925-32.
89. Colucci, P., Pottage, J.C., Robison, H., Turgeon, J., Ducharme, M.P. **Effect of a Single Dose of Ritonavir on the Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered in Healthy Volunteers.** Antimicrob. Agents Chemother, 2009; 53(2):646-650.
90. Colucci, P., Pottage, J.C., Robison, H., Turgeon, J., Schürmann, D., Hoepelman, I.M., Ducharme, M.P. **Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1 – Infected Subjects.** Antimicrob. Agents Chemother, 2009; 53(2):662-669.
91. Fenneteau, F., Turgeon, J., Couture, L., Michaud, V., Li, J., Nekka, F. **Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination.** Theor Biol Med Model, 2009; 15;6(1):2.
92. Hreiche, R., Morissette, P., Zakrzewski-Jakubiak, H., Turgeon, J. **Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs.** J Cardiovascular Pharmacol Ther, 2009, 14(1):28-37.
93. Hreiche, R., Plante, I., David, L.-P., Simard, C., Turgeon, J., Drolet, B. **Impact of glucose concentration on cardiac ventricular repolarization under I_{Kr}/I_{Ks} blocking agents.** J of Molecular and Cellular Cardiology, 2009, 47(2):210-220.
94. Nguyen, T.A., Lordkipanidzé, M., Diodati, J.G., Palisaitis, D.A., Schampaert, E., Turgeon, J., Pharand, C. **Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention; results of a double blind, randomized clinical trial.** J Interv Cardiol, 2009; 22(4):68-77.

95. Rinfret, S., Lussier, MT., Peirce, A., Duhamel, F., Cossette, S., Lalonde, L., Tremblay, C., Guertin, MC., LeLorier, J., Turgeon, J., Hamet, P. **The Impact of a multidisciplinary, information technology supported program on blood pressure control in primary care.** *Circulation*, 2009 May;2(3):170-7.
96. Turgeon, J., Gröning, R., Sathyan, G., Thippawong, J., Richarz, U. **The pharmacokinetics of a long-acting OROS hydromorphone formulation.** *Expert Opin Drug Deliv.* 2010 Jan; 7 (1):137-44.
97. Michaud, V., Simard, C., Turgeon, J. **Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5, inhibition by ketoconazole.** *Drug Metabolism letters*, 2010;4(2):95-103.
98. Michaud, V., Turgeon, J. **Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes** *Drug Metabolism Letters*, 2010, 4(2):69-76.
99. Lordkipanidzé, M., Diodati, J.G., Turgeon, J., Schampaert, E., Palisaitis, D.A., Pharand, C. **Platelet count, not oxidative streee, may contribute to inadequate platelet inhibition by aspirin.** *Interntl J of Cardiology*, 2010 Aug 6; 143:43-50.
100. de Denus, S., Zakrzewski-Jakubiak, M., Barhdadi, A., Leblanc, MH., Racine, N., Bélanger, F., Carrier, M., Ducharme, A., Dubé, MP., Turgeon, J. and White, M. **Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.** *J of Heart and Lung Transplantation*, 2010 Nov 18.
101. Michaud, V. Frappier, M., Dumas, MC, Turgeon, J. **Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism.** *PLoS ONE*, December 2010, 5(12).
102. Hamelin, B.A, Zakrzewski-Jakubiak, M., Robitaille, M., Bogaty, M.D., Labbé, L., Turgeon, J. **Increased risk of myocardial infarction associated with angiotensin-converting enzyme gene polymorphism is age-dependent.** *J of Clin Pharmacol*, 2011;51:1286-1292.
103. Zakrzewski-Jakubiak, M., de Denus, S., Leblanc, M.H., White, M., Turgeon, J. **Enantioselective quantification of carvedolol in human plasma by HPLC in heavily medicated heart failure patients.** *J Pharm Biomed Anal*, 2010 Aug 1; 52(4):636-41.
104. Hreiche, R., Plante, I., Drolet, B., Morissette, P., Turgeon, J. **Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IK_r blockers.** *J of Pharmaceutical Sc*, 2010 Dec 23.
105. O'Hara, G.E., Philippon, F., Gilbert, M., Champagne, J., Michaud, V., Charbonneau, L., Pruneau, G., Hamelin. B.A., Geelen, P., Turgeon, J. **Combined Administration of Quinidine and Propafenone for Atrial Fibrillation : The CAQ-PAF Study.** *J Clin Pharmacol*, DOI: 10.1177/0091270011399574.
106. Colucci, P., Turgeon, J., Ducharme, M.P. **How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence?** *J Pharm Pharmaceut Sci*, 2011, 14(2) 217-226.

107. Lordkipanidzé, M., Diodati, J.G., Palisaitis, D.A., Schampaert, E., Turgeon, J., Pharand, C. **Genetic determinants of response to aspirin: appraisal of 4 candidate genes.** *Thrombosis and Haemostasis*, 2011, 128:47-53.
108. Robidoux A, Rich E, Bureau NJ, Mader S, Laperrière D, Bail M, Tremblay N, Patenaude M, Turgeon J. **A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.** *Curr Oncol*. 2011 Dec;18(6):285-94
109. Caillier, B., Pilote, S., Castonguay, A., Patoine, D., Ménard-Desrosiers, V., Vigneault, P., Hreiche, R., Turgeon, J., Daleau, P., De Koninck, Y., Simard, C., Drolet, B. **QRS widening and QT prolongation under bupropion: A unique cardiac electrophysiological profile.** *Fundam Clin Pharmacol*, 2012, 26(5) :599-608.
110. Michaud, V., Turgeon, J., Flockhart, D., Wainberg, M. **Rôle de la pharmacogénétique dans la réponse antirétrovira de l'infection par le VIH.** *Virologie*, 2011, 15(3) :157-74.
111. Colucci, Ph., Grenier, J., Yue, CS., Turgeon, J., Ducharme, M. **Performance of different population pharmacokinetic algorithms.** *Ther Drug Monitoring*, 2011, 33(5) :583-91.
112. Marin-Leblanc, M., Perreault, S., Bahroun, I., Lapointe, M., Mongrain, I., Provost, S., Turgeon, J., Talajic, M., Brugada, R., Phillips, M., Tardif, JC., Dubé, MP. **Validation of warfarin pharmacogenetic algorithms in clinical practice.** *Pharmacogenomics*, 2012, 13:21-29.
113. Plante, I., Vigneault, P., Drolet, B., Turgeon, J. **Rosuvastatin blocks the hERG current and prolongs cardiac repolarization at clinically relevant concentrations of the drug.** *J of Pharmaceutical Sciences*, DOI 10.1002/jps.22809.
114. Zakrzewski-Jakubiak, H., Doan, J., Lamoureux, P., Singh, D., Turgeon, J., Tannenbaum, C. **Detection and Prevention of Drug-Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450-Based Software.** *American J of Geriatric Pharmacotherapy*, doi:10.1016/j.amjopharm.2011.09.006.
115. Lachance, K., Barhdadi, A., Mongrain, I., Normand, V., Zakrzewski, M., Leblanc, MH., Racine, N., Carrier, M., Ducharme, A., Turgeon, J., Dubé, MP., Phillips, MS., White, M., de Denus, S. **PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients.** *Pharmacogenetics and Genomics* 2012, 22(5):336-343. DOI 10.1097/FPC.0bo13e3283510a35.
116. Michaud, V., Bar-Magen, T., Turgeon, J., Desta, Z., Flockhart, D., Wainberg, M. **The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition,** *Pharmacol Rev*, 2012, 64(3) :803-33.
117. Skrobik, Y., Léger, C., Cossette, M., Michaud, V., Turgeon, J. **Predisposing factors to coma and delirium : Fentanyl and midazolam exposure, CYP3A5, ABCB1 and ABCG2 genetic polymorphisms, and inflammatory factors.** *Critical Care Med* 2013;41:999-1008.
118. De Denus, S., Letarte, N., Hurlimann, T., Lambert, J-P, Lavoie, A., Robb, L., Sheehan, N., Turgeon, J., Vadnais, B. **An Evaluation of Pharmacists' Expectations towards Pharmacogenomics,** *Pharmacogenomics*, 2013, 14(2), 165-175.

119. Michaud, V., Turgeon, J. **Domperidone and sudden cardiac death: how much longer should we wait ?** J of Cardiovascular Pharmacol, 2013 Mar;61(3):215-7..
120. Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J., Tannenbaum, C. **Prevalence and risk of cytochrome P450 drug-drug interactions in older hospitalized patients with polypharmacy**, Ann of Pharmacotherapy, 2013 March, Vol 47: 324-332.
121. Dubé, M.P., Zetler, R., Barhdadi, A., Brown, A., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Feroz Zada, Y., Provost, S., deDenus, S., Réhaume, E., Turgeon, J., Phillips, M., Tardif, J.C. **CKM and LILRB5 are associated with serum levels of creatine kinase in statin users.** Circulation: Cardiovascular Genetics, 2014; 7: 880-886.
122. Lu, J., Michaud, V., Guilarte Moya Liliam, G., Gaudette, F., Leung, Yat Hei, Turgeon, J. **Effects of β -blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2).** J Pharmacol Exp Ther. 2015; 352: 552-558.
123. Shaw, K., Amstutz, U., Kim, R., Lesko, L.J., Turgeon, J., Michaud V., Hwang, S, Ito, S., Carleton, B.C., and the CPNDS clinical recommendation group¹⁰, **Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.** Therapeutic Drug Monitoring. 2015; 37: 428-436.
124. Gaudette, F., Sirhan-Daneau, A., St-Onge, M., Turgeon, J., Michaud V. **Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.** Journal of Chromatography B. 2016; 1008:174-80.
125. Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J., Michaud V. **Evaluation of limited sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation.** Ther Drug Monit. 2016; 38:414-418.
126. Turgeon J., Michaud V. **Clinical decision support systems: Great promises for better management of patients' drug therapy.** Expert Opin Drug Metab Toxicol. 2016; 12:993-995.
127. Huguet, J., Lu, J., Gaudette, F., Chiasson, J.-L., Hamet, P., Michaud, V., Turgeon, J. **No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.** Eur J. Clinical Pharmacology. 2016; 72(8): 925-931.
128. Grangeon A., Gravel S, Gaudette F., Turgeon, J., Michaud V., **Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human.** J. Chromatogr. B 2017; 1040:144-158.
129. Bain KT, Knowlton CH, Turgeon J. **Medication Risk Mitigation: Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research.** Clin Geriatr Med. 2017 May;33(2): 257-281.
130. Maximos S, Chamoun M, Gravel S, Turgeon J., Michaud V. **Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.** Pharmaceutics. 2017 Sep 26;9(4).

131. Turgeon J, Michaud V, Steffen L. **The Dangers of Polypharmacy in Elderly Patients.** JAMA Intern Med. 2017 Oct 1; 177 (10):1544
132. Leung YH, Turgeon J, Michaud V. **Study of Statin-and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells.** Pharmaceutics. 2017 Oct 10; 9(4). pii: E42.
133. Schwartz Ej, Turgeon J, Patel J, Patel P, Shah H, Issa AM, Knowlton OV, Knowlton CH, Bain KT. **Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care.** J Am Board Fam Med. 2017 Nov-Dec; 30 (6): 701-714.
134. Leung YH, Belanger F, Lu J, Turgeon J, Michaud V. **Effects of a series of acidic drugs on L-lactic acid transport by the monocarboxylate transporters MCT1 and MCT4.** Curr Pharm Biotechnol. 2017;18:1141-1150.
135. Gravel S, Chiasson JL, Dallaire S, Turgeon J, Michaud V. **Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.** BMJ Open. 2018 Feb 8;8(2):e020922.
136. de Denus S, Dubé MP, Fouodjio R, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S, Normand V, Mongrain I, Langlois M, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators. **A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.** Pharmacogenomics. 2018 May;19(7):599-612. Epub 2018 Apr 27.
137. Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. **Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.** Clin Cardiol. 2018 May;41(5):576-585. Epub 2018 May 15.
138. Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. **Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE).** J Am Pharm Assoc (2003). 2018 May - Jun;58(3):281-289.e1. Epub 2018 Mar 27.
139. Cicali B, Michaud V, Knowlton CH, Turgeon J. **Application of a novel medication-related risk stratification strategy to a self-funded employer population.** Benefits Quarterly 2018; Second Quarter:49-55.
140. Huguet J, Gaudette F, Michaud V, Turgeon J. **Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes.** Xenobiotica. 2019;49:187-199.
141. Clermont V, Grangeon A, Barama A, Turgeon J, Lallier M, Malaise J, Michaud V. **Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine.** Br J Clin Pharmacol. 2019 Jun;85(6):1367-1377. Epub 2019 Apr 13.
142. Gravel S, Panzini B, Belanger F, Turgeon J, Michaud V. **A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.** International Journal of Molecular Sciences. 2019 Jul 2;20(13). PII: E3257.

143. Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Bélanger F, Turgeon J. **Impact of *GSTA1* Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.** *Pharmaceutics*. 2019 Sep 1;11(9). PII: E440.
144. Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V. **Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS/MS-based targeted proteomics.** *J Pharma Biomedical Anal*. 2019 Sep 5;173:96-107. Epub 2019 May 4.
145. Gravel S, Chiasson JL, Gaudette F, Turgeon J, Michaud V. **Use of 4 β -Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals with Type 2 Diabetes.** *Clin Pharmacol Ther*. 2019 Oct;106(4):831-840. Epub 2019 Jun 5.
146. Gravel S, Chiasson JL, Turgeon J, Grangeon A, Michaud V. **Modulation of CYP450 Activities in Patients with Type 2 Diabetes.** *Clin Pharmacol Ther*. 2019 Dec;106(6):1280-1289. Epub 2019 Jul 9.
147. Turgeon J, Michaud V, **Medication Monitor: Decreasing Adverse Drug Events.** *Today's Geriatric Medicine*, January/February 2020;13-1:8
148. Galiano L, Hingle N, Kurlin K, Michaud V, Dow P, Turgeon J, **Mechanisms and Clinical Relevance of Drug-Induced Long QT Syndrome: Block of hERG, Drug Metabolism and Drug Transport in the Human Heart.** *Annals of Pharmacology and Pharmaceutics*, 07 Jan 2020; 5(2):1176.
149. Bain KT, McGain D, Cicali EJ, Kwolton CH, Michaud V, Turgeon J, **Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics.** *Clinical Case Reports* 2020; 8:305-312.
150. Al Rihani SB, Deodhar M, Dow P, Michaud V, Turgeon J, **Is Dexamethasone a Substrate, an Inducer, or a Substrate-Inducer of CYP3As?** *Archives of Pharmacy & Pharmacology Research* 20 Feb 2020; 2(4)
151. Matos A, Bain KT, Bankes DL, Furman A, Skalski B, Verzicco J, Turgeon J, **Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics Are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia.** *Pharmacy (Basel)*. 2020 Apr 8;8(2): E63.
152. Bankes DL, Jin H, Finnel S, Michaud V, Knowlton CH, Turgeon J, Stein A. **Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly.** *Pharmacy (Basel)*. 2020 May 20;8(2).
153. Deodhar M, Dow P, Al Rihani SB, Turgeon J, Michaud V. **An illustrative case of phenoconversion due to multi-drug interactions.** *Clin Case Rep J*. 2020;1(3):1–6.
154. Bardolia C, Michaud V, Turgeon J, Amin N. **Deprescribing Dual Therapy in Benign Prostatic Hyperplasia: A Patient Case.** *Clin Case Rep*. 10:5 (2020)

155. Furman A, Bardolia C, Meyer K, Turgeon J, Amin N. **Identifying Adverse Drug Effects of Amiodarone through a Pharmacist-Led Comprehensive Review.** Clin Case Reports. 2020;10(7). DOI: 10.37421/jccr.2020.10.1370
156. Wright SA, Bardolia C, Bankes D, Amin N, Turgeon J. **Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Cough Resulting in Prescribing Cascade.** Clin Case Reports. 2020;10(7). DOI: 10.37421/jccr.2020.10.1368
157. Bingham J, Arlington L, Madhat F, Michaud V, Turgeon J. **Adherences Takes Hit in Pandemic.** Pharmacy Times. June 2020.
158. Michaud V, Deodhar M, Arwood M, Al Rihani SB, Dow P, Turgeon J. **ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System.** Journal Clinical Medicine. 2020 July 3; 9(7), 2096
159. Al Rihani SB, Smith MK, Bikmetov R, Deodhar M, Dow P, Turgeon J, Michaud V **Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.** Journal Clinical Medicine. 2020 Aug 10;9(8):E2591.
160. Matos A, Bankes D, Bain K, Ballinghoff T, Turgeon J. **Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift is Needed to Ameliorate the Ongoing Opioid Epidemic.** Pharmacy. August 25, 2020, 8, 154
161. Shoojat S, Bardolia C, Turgeon J, Amin N. **Medication-Related Problems in Older Adults and the Importance of Comprehensive Medication.** ClinCase Reports. 2020.10(8). DOI: 10.37421/jccr.2020.10.1377
162. Kassem I, Sanche S, Li J, Bonnefois G, Dube M, Rouleau J, Tardif J, White M, Turgeon J, Nekka F, Denus S. **Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure.** Clin Transl Sci. 2020; 0,1-10.
163. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. **Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice.** Pharmaceutics. 2020 Sep 4.;12(9): E846.
164. Michaud V, Dow P, Al Rihani SB, Deodhar M, Arwood M, Cicali B, Turgeon J. **Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs.** Clin Transl Sci. 2020 Sep 5. doi: 10.1111/cts.12882. Online ahead of print
165. Ballinghoff T, Bain KT, Matos A, Bardolia C, Turgeon J, Amin NS. **Opioid response in an individual with altered cytochrome P450 2D6 activity: implications of a pharmacogenomics case.** Clin Case Rep J. 2020;1(6):1–4.
166. Bingham J, Michaud V, Turgeon J, Axon D. **Effectiveness of an Advanced Clinical Decision Support System on Clinical Decision-Making Skills in a Call Center Medication Therapy Management Pharmacy Setting: A Pilot Study.** Pharmacy 2020 Nov 25, 8(4).

167. Bardolia C, Matos A, Michaud V, Turgeon J, Bain KT, Amin NS, **Utilizing Pharmacogenomics to Reduce Adverse Drug Events**. Am J Biomed Sci & Res. 2020 - 11(3).
168. Bingham J, Tranchina K, Turgeon J. **Telepharmacy Offers Opportunity Amid Pandemic**. Pharmacy Times. January 2021.
169. Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. **Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition**. Pharmaceutics. 2021 Jan 23;13(2):148.
170. Tranchina K, Turgeon J, Bingham J. **Integrating a novel medication risk score and use of an advanced clinical decision support system into a pharmacist and nurse-coordinated transition of care program to mitigate drug interactions**. Clin Case Rep J. 2021 Jan 28;2(1):1–5.
171. Michaud V, Turgeon J. **Precision Medicine: Applied Concepts of Pharmacogenomics in Patients with Various Diseases and Polypharmacy**. Pharmaceutics. 2021 Feb 02; 13(2):197.
172. Ha M, Amin N, Meyer K, Turgeon J, Bardolia C. **Balancing Sleep and Motor Symptoms: A Case Report of Managing Insomnia in Parkinson's Disease**. Clin Case Rep 11(5) 2021 March 30: 1432.
173. Al Rihani S B, Darakjian L, Deodhar M, Dow P, Turgeon J, Michaud V. **Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level**. Int J Mol Sci. 2021 April 03, 22(7), 3742.
174. Ratigan A, Michaud V, Turgeon J, Bikmetov R, Gaona G, Anderson H, Pulver G, Pace W. **Longitudinal Association of a Medication Risk Score with Mortality Among Ambulatory Patients Acquired Through Electronic Health Record Data**. Journal of Patient Safety. 2021 March 24, Epub ahead of print.
175. Smith MK, Bikmetov R, Al Rihani SB, Deodhar M, Hafermann M, Dow P, Turgeon J, Michaud V. **Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study**. Clin Transl Sci. 2021 Mar 30. Epub ahead of print. PMID: 33786990.
176. Darakjian L, Deodhar M, Turgeon J, Michaud V. **Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity**. International Journal of Molecular Sciences. 2021 May; 22(9):4967.
177. Bingham J, Stanislaw J, Warholak T, Scovis N, Axon R, Turgeon J, Marupuru S. **Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth**. Int J Environ Res Public Health. 2021 June 18;18(12):6560.
178. Matos A, Dow P, Bingham J, Michaud V, Lesko L, Knowlton C, Turgeon J, **Tabula Rasa HealthCare company profile: involvement on pharmacogenomic and personalized medicine research**. Pharmagenomics Epub ahead of print. 2021 July 21.

179. Pizzolato K, Meyer K, Matos A, Turgeon J, Bardolia C, **Pharmacist-led medication review identifies and mitigates fall-risk-increasing drugs and multi-drug interactions**. Clin Case Rep. 2021 July 07; 11(7).
180. Long T, Cristofolletti R, Cicali B, Michaud V, Dow P, Turgeon J, Schmidt S. **Physiologically-based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition**. J Clin Pharmacol. 2021 Aug 12. doi: 10.1002/jcph.1951. Epub ahead of print. PMID: 34383318.
181. SanFilippo S, Michaud V, Wei J, Bikmetov R, Turgeon J, Brunetti L. **Classification and Assessment of Medication Risk in the Elderly (CARE): Use of a Medication Risk Score to Inform Patients' Readmission Likelihood after Hospital Discharge**. J. Clin. Med. 2021 Aug 31; 10, 3947
182. Ha M, Meyer K, Matos A, Turgeon J, Bardolia C. **Optimizing medications in patients with cardiovascular disease: a case report on unrecognized prescribing cascades in older adults**. Clin Case Rep J. 2021 Sept 03; 2(3):1–5.
183. Del Toro-Pagán NM, Matos A, Thacker D, Turgeon J, Amin NS, Michaud V. **Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report**. Medicina. 2021 Sept 10; 57(9):955
184. Deodhar M, Turgeon J, Michaud V. **Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism**. Pharmaceutics 2021 Sept 14; 13(9):1466.
185. Michaud V, Smith MK, Bikmetov R, Dow P, Johnson J, Stein A, Finnel S, Jin H, Turgeon J. **Association of the MedWise Risk Score with health care outcomes**. Am J Manag Care. 2021 Sept 27; (16 Suppl): S280-S291
186. Bankes D, Pizzolato K, Finnel S, Awadalla MS, Stein A, Johnson J, Turgeon J. **Medication-related problems identified by pharmacists in an enhanced medication therapy management model**. Am J Manag Care. 2021 Sep 27;(16 Suppl): S292-S299
187. Stein A, Finnel S, Bankes D, Jin H, Awadalla MS, Johnson J, Turgeon J. **Health outcomes from an innovative enhanced medication therapy management model**. Am J Manag Care. 2021 Sep 27;(16 Suppl): S300-S308.

NIH Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/1Vaw9R9Xfuss9C/bibliography/public/>

Abstracts:

1. Bélanger P.M., Lalande, M., Turgeon, J., Doré, F., Labrecque, G. **Variations temporelles de la N-acétylation de l'isoniazide chez le rat et de la sulfamérazine chez l'homme.** Club de recherche clinique du Québec. Union Méd. Can., 1981; 110 : S-12.
2. Bélanger, P.M., Turgeon, J. **Substrate Enantioselectivity of the Microsomal N-Oxydation Pathway.** Association des facultés de pharmacie du Canada, Montréal, 1983.
3. Grech-Bélanger, O., Turgeon, J., Gilbert M. **Stereoselective Elimination of Mexiletine in Human Subjects.** American Pharmaceutical Association Conference, Montréal, 1984.
4. Turgeon, J., Grech-Bélanger, O., Gilbert, M. . **Pharmacokinetics of Enantiomers of Mexiletine in Man.** Federation International of Pharmaceutics, Montréal, 1985.
5. Turgeon, J., Grech-Bélanger, O., Gilbert M.. **Cigarette Smoking and Mexiletine Pharmacokinetics.** Congrès de l'Association des facultés de pharmacie du Canada. J. Clin. Invest. Med., 1985; 8:C6.
6. Grech-Bélanger, O., Turgeon J., Bélanger, P.M. **Species Variation in the Stereoselective Metabolism of Mexiletine.** Congrès de l'Association des facultés de pharmacie du Canada. J. Clin. Invest. Med. 1986;9.
7. Turgeon, J., Grech-Bélanger, O., Gilbert, M. **Erythrocyte and Serum Distribution of Mexiletine in Man.** Congrès de l'Association des faculté de pharmacie du Canada. J. Clin. Invest. Med., 1986:9.
8. Turgeon, J., Grech-Bélanger, O. **Resolution of RS-Mexiletine.** Congrès de l'Association des facultés de pharmacie du Canada, Jasper, 1987.
9. Bélanger, P.M., Grech-Bélanger, O., Turgeon, J., Tran Bang, T. **Differential Effects of Cimetidine on the Microsomal Metabolism of Antipyrine and Mexiletine in Rabbit Liver.** Japanese and United States Congress of Pharmaceutical Sciences. J. Pharm. Sci., 1987; 76:S-39.
10. Grech-Bélanger, O., Turgeon, J., Lalande, M. **A New Metabolite of Mexiletine: Isolation, Identification and Species Differences.** Japanese and United States Congress of Pharmaceutical Sciences. J. Pharm. Sci., 1987; 76: S-33.
11. Harron, D.W.G., Grech-Bélanger, O., Turgeon, J., Uprichard, A.C.G. **The Antiarrhythmic Potency of Mexiletine Enantiomers.** 72nd Annual Meeting, Federation American Societies for Experimental Biology and Guest Societies. FASEB J., 1988; 2:A608.
12. Turgeon, J., Grech-Bélanger, O., Bélanger, P.M. **The Stereoselective Metabolism of Mexiletine.** 31st Annual Meeting, Canadian Federation of Biological Societies, Québec, 1988.
13. Altemeier, W.A., Turgeon, J., Wisialowski, T., Wikswo, Jr. P., Roden, D.M. **Contrasting Effects of Class I and class III Antiarrhythmics on Virtual Cathode Dimension.** 61st Annual Scientific Session, American Heart Association Meeting. Circulation, 1988: 78:II-414.
14. Lineberry, M.D., Lee, J.T., Turgeon, J., Crawford, D.M., Horrell, K.D., Woosley, R.L., Roden, D.M. **Encainide Plus Lidocaine or Mexiletine in Patients with Sustained Ventricular Tachycardia.** 61st Annual Scientific Session, American Heart Association Meeting. Circulation, 1988; 78:II-627.

15. Funck-Brentano, C., Turgeon, J., Woosley, R.L., Roden, D.M. **Reversal of Encainide Effects Due to a Genetically-Determined Interaction with Low Dose Quinidine.** 61st Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1988; 78:II-498.
16. Funck-Brentano, C., Turgeon, J., Kroemer, H.K., Woosley, R.L., Roden, D.M. **Conséquences pharmacocinétiques et pharmacodynamiques de l'interaction entre quinidine et propafénone ou encainide.** Réunion de la Société française de cardiologie. *Arch. Mal. Coeur*, 1988; 82:965.
17. Kroemer, H.K., Turgeon, J., Gray, H.T., Meese, C.O., Roden, D.M. **In Vitro Electrophysiology and In Vivo Disposition of Flecainide Enantiomers.** American Society of Clinical Pharmacology and Therapeutics Meeting. *Clin. Pharmacol. Ther.* 1989; 45:179.
18. Kroemer, H.K., Turgeon, J., Thomas, T., Roden, D.M. **Accumulation of Propafenone Glucuronide during Chronic Oral Therapy in Man.** American Society of Clinical Pharmacology and Therapeutics Meeting. *Clin. Pharmacol. Ther.*, 1989; 45:180.
19. Turgeon, J., Kroemer, H.K., McAllister, C.B., Branch, R.A., Wilkinson, G.R., Woosley, R.L., Roden, D.M. **Heterogeneity in the Extensive Metabolizer Phenotype of Encainide.** American Society of Clinical Pharmacology and Therapeutics Meeting. *Clin. Pharmacol. Ther.*, 1989; 45:181.
20. Turgeon, J., Funck-Brentano, C., Pavlou, H., Woosley, R.L., Roden, D.M. **Differential Sensitivity of P450_{ab1} Substrates to Inhibition by Quinidine in Man.** IVth World Conference on Clinical Pharmacology & Therapeutics. *Eur. J. Clin. Pharmacol.*, 1989; 36:A41.
21. Turgeon, J., Pavlou, H., Funck-Brentano, C., Roden, D.M. **Genetically Determined Interaction of Encainide and Quinidine in Patients with Arrhythmias.** 62nd Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1989; 80:SII-326.
22. Turgeon, J., Li, P., Branch, R.A., Roden, D.M. **Acute Alteration of Antiarrhythmic Drug-Induced QRS Widening by Modulation of Angiotensin II.** 62nd Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1989; 80:SII-137.
23. Turgeon, J., Balsler, J.R., Bennett, P.B., Roden, D.M. **Isoproterenol (ISO) Blunts Quinidine-Induced Inhibition of the Cardiac Delayed Rectifier I_K.** 34th Annual Biophysical Society Meeting. *Biophys. J.*, 1990; 57:514A.
24. Birgersdotter, U.M., Turgeon, J., Wong, W., Roden, D.M. **Stereoselective Genetically-Determined Interaction of Flecainide and Quinidine.** American Federation for Clinical Research Meeting. *Clin. Res.*, 1990; 38:338A.
25. Kroemer, H.K., Turgeon, J., Prakash, C., Funck-Brentano, C., Roden, D.M. **Determination of Debrisoquine/Sparteine Phenotype during Chronic Propafenone Therapy: A New Approach Using Intact Conjugates.** IUPHAR Meeting, *Eur. J. Pharmacol.*, 1990; 183:1074.
26. Turgeon, J., Grech-Bélanger, O., Lalande, M., Bélanger, P.M., Paré, J.R. **Characterization of Mexiletine-N-Hydroxyglucuronide in Urine.** 2nd International Symposium on Applied Mass Spectrometry in the Health Sciences, Barcelona, 1990.
27. Turgeon, J., Bennett, P.B., Roden, D.M. **N-Acetylprocainamide (NAPA) Blocks an Early Component of Outward Potassium Current.** 63th Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1990; 82:SIII-528.

28. Wong, W., Birgersdotter U., Turgeon, J., Roden, D.M. **Steady-State Pharmacokinetics and Pharmacodynamics of the Class III Antiarrhythmic Sematilide.** 63th Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1990; 82:SIII-198.
29. Turgeon, J., Wisialowski T., Wong, W., Roden, D.M. **Angiotensin II (AII) and Isoproterenol (ISO) Alter the Effects of Na⁺ Channel Block *In Vivo*.** 63th Annual Scientific Session, American Heart Association Meeting. *Circulation*, 1990; 82:SIII-647.
30. Turgeon, J., Pavlou, H.N., Funck-Brentano, C., Roden, D.M. **Stereoselective Excretion of Encainide in Man.** 92nd Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. *Clin. Pharmacol. Ther.*, 1991; 49:158.
31. Turgeon, J., Wiggins, S., Bennet, P.B., Roden, D.M. **Time-Dependent Block of Outward K⁺ Current by the Diuretic Indapamide in Guinea Pig Myocytes.** 35th Annual Biophysical Society Meeting. *Biophys. J.*, 1991; 59:278a.
32. Kingma, J.G. Jr, Fiset, C., Lacoursière, L., Turgeon, J. **Effects of Indapamide on Reperfusion-Induced Arrhythmias.** FASEB Meeting 1991. *FASEB J.* 1991; 5:A1216.
33. Fiset, C., Giguère, R., Kroemer, H.K., Gilbert, M., Rouleau, J.R., Mikus, G., Nguyen, N.N., Eichelbaum, M., Bélanger, P.M., Turgeon, J. **Genetically-Determined Pharmacokinetic Interaction Between Mexiletine and Quinidine in Man.** Société canadienne de recherche clinique. *Clin. Invest. Med.*, 1991; 14:A18.
34. Turgeon, J., Fiset, C., Kingma, M.L., Lacoursière, L., Kingma, J.G. Jr. **Can Sulfonamide Diuretics Prevent Reperfusion-Induced Arrhythmias?** Société canadienne de recherche clinique. *Clin. Invest. Med.*, 1991; 14:A15.
35. Fiset, C., Giguère, R., Gilbert, M., Moerike, K., Rouleau, J.R., Kroemer, H.K., Eichelbaum, M., Bélanger, P.M., Turgeon, J. **Polymorphisme génétique du métabolisme de la mexilétine (MEX).** 33^e Réunion annuelle du Club de recherche clinique du Québec. *Med. Sciences*, 1991; 7:(supp 1) 59.
36. Turgeon, J., Wiggins, S., Bennett, P.B., Roden, D.M. Blocage sélectif des composantes rapide (IKr) et lente (IKs) du courant K⁺ delayed rectifier par le N-acétylprocainamide (NAPA) et l'indapamide (IND). 33^e Réunion annuelle du Club de recherche clinique du Québec. *Med. Sciences*, 1991; 7:(suppl 1) 59.
37. Turgeon, J., Houde, A., Bélanger, P.M. **Differential Inhibition of N-Hydroxy-Procainamide Formation by Quinine and Quinidine in Rat Liver Microsomes.** Congrès de l'Association des facultés de pharmacie du Canada, Winnipeg, 1992.
38. Fiset, C., Turgeon, J. **HPLC Assay for Determination of Sotalol Enantiomers in Biological Fluids.** Congrès de l'Association des facultés de pharmacie du Canada, Winnipeg, 1992.
39. Turgeon, J., Fiset, C., Giguère, R., Gilbert M., Moerike, K., Rouleau, J.R., Kroemer, H.K., Eichelbaum, M., Grech-Bélanger, O., Bélanger, P.M. **Influence of Debrisoquine Phenotype and of Quinidine on Mexiletine Disposition.** Congrès de l'Association des facultés de pharmacie du Canada, Winnipeg, 1992.
40. Abolfathi, Z., Bélanger, P.M., Turgeon, J. **HPLC Assay for the Stereoselective Determination of Mexiletine in Plasma.** Congrès de l'Association des facultés de pharmacie du Canada, Winnipeg, 1992.

41. Turgeon, J., Grech-Bélanger, O., Bélanger, P.M. **The Microsomal Metabolism of Mexiletine Enantiomers in Rabbit Liver Microsomes: Involvement of Different Cytochrome P-450 Isozymes.** Annual Meeting, Canadian Federation of Biological Societies, Vancouver, 1992.
42. Abolfathi, Z., Fiset, C., Gilbert, M., Rouleau, J.R., Bélanger, P.M., Turgeon, J. **Role of Cytochrome P450IID6 in the Stereoselective Disposition of Mexiletine in Man.** Société canadienne de recherche clinique, Clin. Invest. Med., 1992; 15:(suppl A) A19.
43. Fiset, C., Phillipon, F., Gilbert, M., Turgeon, J. **Stereoselective Disposition of *dl*-Sotalol under Steady-State Conditions in Patients.** Société canadienne de recherche clinique, Clin. Invest. Med., 1992; 15:(suppl A) A19.
44. Fiset, C., Turgeon, J. **Modulation of Sotalol-Induced Prolongation of Refractoriness by Indapamide in Dogs.** Canadian Cardiovascular Society. Can. J. Cardiol., 1992; 45:114B.
45. Daleau, P., Turgeon, J. **Inhibition of Both Components of the Delayed Rectifier K⁺ Current by Triamterene in Guinea Pig Ventricular Myocytes.** Canadian Cardiovascular Society. Can. J. Cardiol. 1992; 45:92B.
46. Daleau, P., Turgeon, J. **Characterization of the Inhibition of the Delayed Rectifier (I_K) Components by Triamterene in Guinea Pig Ventricular Myocytes.** 37th Annual Biophysical Society Meeting. Biophys. J. 1993; 64:A316.
47. Coquet, A., Fiset, C., Belley, D., Turgeon, J. **Sensitive HPLC Assay for Determination of the Diuretic Agent Indapamide.** Congrès de l'Association des facultés de pharmacie du Canada; Biotechnologie pharmaceutique. Vancouver, août 1993.
48. Fortin, A., Coquet, A., Turgeon, J. **Selective and Sensitive HPLC Assay for Determination of the Antiarrhythmic Agent Procainamide and Its Metabolite (NAPA).** Congrès de l'Association des facultés de pharmacie du Canada; Biotechnologie pharmaceutique. Vancouver, août 1993.
49. Abolfathi, Z., Turgeon, J. **Stereoselective Recovery of Mexiletine (MEX) Enantiomers During Liquid-Liquid Extraction from Biological Fluids in Presence of NaOH.** Congrès de l'Association des facultés de pharmacie du Canada; Biotechnologie pharmaceutique. Vancouver, août 1993.
50. Fiset, C., Kingma, M.L., Kingma, J.G. Jr., Turgeon, J. **Effects of Indapamide and Chlorthalidone on Reperfusion-Induced Arrhythmias in Rat and Guinea Pig.** Congrès de l'Association des facultés de pharmacie du Canada; Biotechnologie pharmaceutique. Vancouver, août 1993.
51. Daleau, P., Turgeon, J. **Inhibition of Time-Dependent Outward Currents by Trimaterene Suggests the Presence of a Third Component of I_K in Guinea Pig Ventricular Myocytes.** XVth Congress of the European Society of Cardiology. Eur. Heart J. 1993;134:36.
52. Abolfathi, Z., Fiset, C., Gilbert, M., St-Maurice, F., Bélanger, P.M., Turgeon, J. **Disposition of Mexiletine Enantiomers During Caffeine Administration: Role of Cytochrome P450IA2.** Canadian Society of Clinical Investigation. Clin Invest Med 1993;16:B17.
53. Fiset, C., Turgeon, J. **Potentialiation of Sotalol Electrophysiologic Effects by Indapamide.** Canadian Cardiovascular Society. Can J Cardiol 1993;9:134^E.

54. Daleau, P., Bennett, P.B., Roden, D.M., Turgeon, J. **Indapamide (IND) Blocks Outward Currents of Guinea Pig Ventricular Myocytes.** Canadian Cardiovascular Society. Can J Cardiol 1993;9:125^e.
55. Daleau, P., Turgeon, J. **Comparative Effects of Nisoldipine (NIS) and Cd²⁺ Used During Assessment of the Delayed Rectifier (I_K) Properties.** Can J Cardiol 1993;9:133^e.
56. Daleau, P., Turgeon, J. **Modulation of the Delayed Rectifier K⁺ Current (I_K) by Angiotensin II (AII).** Can J Cardiol 1993;9:133^e.
57. Roy, S., Robitaille, M.N., Belley, D., Poirier, L., Turgeon, J. **Relation possible entre le polymorphisme génétique de la débrisoquine 4-hydroxylase (CYP2D6) et la toux induite par les inhibiteurs de l'enzyme de conversion de l'angiotensine (IECA).** 35^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1993;9 (suppl 1);15.
58. Turgeon, J. **Certains diurétiques possèdent une activité électrophysiologique cardiaque et peuvent potentialiser les effets des agents antiarythmiques de Classe III.** Matinée des chercheurs boursiers. 35^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1993;9 (suppl 1):10.
59. Fiset, C., Turgeon, J. **La coadministration d'indapamide potentialise les effets électrophysiologiques de classe III du sotalol.** 35^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1993;9 (suppl 1);15.
60. Daleau, P., Turgeon, J. **Effets électrophysiologiques cardiaques d'agents diurétiques.** 35^e Réunion annuelle du Club de recherches cliniques du Québec. Med. Sciences 1993;9 (suppl 1);15.
61. Fortin, A., Coquet, A., Houde, A., Bélanger, P.M., Turgeon, J. **Évaluation du rôle du cytochrome P450IID6 (CYP2D6) dans le métabolisme de la procainamide.** 35^e Réunion annuelle du Club de recherches cliniques du Québec. Med. Sciences 1993;9 (suppl 1);15.
62. Daleau, P., Turgeon, J. **Angiotensin II Modulates Outward K⁺ Currents (I_K and I_{K1}).** 38th Annual Biophysical Society Meeting. Biophys. J. 1994;66.
63. Daleau, P., Turgeon, J. **Comparative Effects of Nisoldipine and Cadmium on the Delayed Rectifier K⁺ Current (I_K) of Guinea Pig Ventricular Myocytes.** 38th Annual Biophysical Society Meeting. Biophys. J. 1994;66:.
64. Turgeon, J., Roy, S., Belley, D., Poirier, L., Robitaille, N.M. **Link Between ACE Inhibitors Associated Cough and Xba I DNA Restriction Fragments of Mutant Alleles of CYP2D6.** 15th Scientific Meeting of the International Society of Hypertension. J. Hypert., 1994;12:S154.
65. Turgeon, J., Bogaty, P., Asselin, M.J., Genest, M., Labbé, L., Lefez, C., Robitaille, N.M. **ACE Genotype Differs among Young Cardiac and Young Healthy Subjects.** Congrès de l'Association des facultés de pharmacie du Canada. Charlottetown, mai 1994.
66. Abolfathi, Z., Pakdel, H., Beaune, P., Turgeon, J. **The N-Oxydation of Mexiletine is Selectively Mediated by CYP1A2.** Congrès de l'Association des facultés de pharmacie du Canada. Charlottetown, mai 1994.

67. Labbé, L., Lefez, C., Asselin, M.J., Turgeon, J. **CYP2D6 Phenotype as Determined by Debrisoquine Metabolic Ratio is Modified by Cigarette Smoking.** Congrès de l'Association des facultés de pharmacie du Canada. Charlottetown, mai 1994.
68. Lessard, E., Groleau, M.F., Turgeon, J. **L'indapamide potentialise les effets électrophysiologiques de classe III du N-acétylprocainamide.** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:25.
69. Daleau, P., Lessard, E., Groleau, M.F., Turgeon, J. **La prolongation de l'intervalle QT induite par l'érythromycine peut s'expliquer par une inhibition d'I_{Kr}, composante rapide du courant rectifiant retardé.** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:24.
70. Turgeon, J., Lefez, C., O'Hara, G., Gilbert, M., Gleton, O., Plante, S. **Modulation de la repolarisation cardiaque par la diphenhydramine (DPH).** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:24.
71. Labbé, L., Lefez, C., Asselin, M.J., Turgeon, J. **Modification du phénotype de la débrisoquine 4-hydroxylase (CYP2D6) par le tabagisme.** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:24.
72. Robitaille, N.M., Bogaty, P., Asselin, M.J., Genest, M., Labbé, L., Lefez, C., Turgeon, J. **Prévalence du génotype DD du polymorphisme de l'enzyme de conversion de l'angiotensine chez les jeunes cardiaques.** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:24.
73. Abolfathi, Z., Pakdel, H., Beaune, P., Turgeon, J. **Rôle des différentes isoenzymes du cytochrome P450 dans la N-oxydation de la mexilétine.** 36^e Réunion annuelle du Club de recherches cliniques du Québec. Med Sciences 1994;10:24.
74. Turgeon, J., Asselin, M.J., Genest, M., Labbé, L., Lefez, C., Poirier, L., Robitaille, N.M. **Higher Prevalence of CYP2D6 44kb Allele in Patients Experiencing Cough During Therapy with Angiotensin Converting Enzyme (ACE) Inhibitors.** Canadian Cardiovascular Society. Can. J. Cardiol. 1994;10:73C.
75. Turgeon, J., Lessard, E., Bussière, S., Groleau, M.F. **Diuretics Potentiate Monophasic Action Potential (MAP) Prolonging Effects of Class III Antiarrhythmics.** Canadian Cardiovascular Society. Can. J. Cardiol. 1994; 10:94C.
76. Robitaille, N.M., Bogaty, P., Asselin, M.J., Genest, M., Labbé, L., Lefez, C., Turgeon, J. **Genotype Distribution of the Angiotensin Converting Enzyme Insertion/Deletion (I/D) Polymorphism Differs among Young Cardiac and Young Healthy Subjects.** Canadian Cardiovascular Society. Can. J. Cardiol. 1994;10:73C.
77. Daleau, P., Turgeon, J. **Prolongation of QT Interval Induced by Erythromycin (ERY) May Be Explained by an Inhibition of I_{Kr}.** Canadian Cardiovascular Society. Can. J. Cardiol., 1994;10:123C.
78. Turgeon, J., Lefez, C., Plante, S., Gleton, O., O'Hara, G., Gilbert, M. **Diphenhydramine (DPH) Lengthens QTc in Man and Monophasic Action Potential Duration (MAPD₉₀) in Guinea Pig Heart.** Canadian Cardiovascular Society. Can. J. Cardiol., 1994;10:123C.
79. Turgeon, J., Lessard, E., Bussière, S., Groleau, M.F., Daleau, P. **Diuretics Potentiate Monophasic Action Potential Prolonging Effects of Class III Antiarrhythmic Drugs in Isolated Guinea Pig Hearts.** 67th Annual Scientific Session, American Heart Association Meeting. Circulation, 1994;90:I-249.

80. Lefez, C., Plante, S., Gleeton, O., O'Hara, G., Gilbert, M., Turgeon, J. **Diphenhydramine Lengthens QTc in Man and Prolongs Monophasic Action Potential Duration in Isolated Guinea Pig Heart.** 67th Annual Scientific Session, American Heart Association Meeting. Circulation, 1994;90:I-248.
81. Daleau, P., Turgeon, J. **Prolongation of QT Interval Induced by Erythromycin May Be Explained by an Inhibition of the Rapid Component of the Delayed Rectifier Potassium Current I_{Kr}.** 67th Annual Scientific Session, American Heart Association Meeting. Circulation, 1994;90:I-248.
82. Robitaille, N.M., Bogaty, P., Asselin, M.J., Genest, M., Labbé, L., Lefez, C., Turgeon, J. **Genotype Distribution of the Angiotensin Converting Enzyme Insertion/Deletion (I/D) Polymorphism Differs among Young Cardiac and Young Healthy Canadian Subjects.** 67th Annual Scientific Session, American Heart Association Meeting. Circulation, 1994;90:I-110.
83. Robitaille, N.M., Turgeon, J., Roy, S., Belley, D., Poirier, L. **Relation entre la toux associée aux inhibiteurs de l'enzyme de conversion et les allèles mutantes du CYP2D6.** XIV^e Journées de l'hypertension artérielle, Paris, décembre 1994.
84. Turgeon, J., Labbé, L., Lefez, C., LeBel, M. **Debrisoquine Metabolic Ratio (DMR) Distribution Differs among Smokers and Non-Smokers.** Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1995;57:150.
85. Labbé, L., Lefez, C., Gilbert, M., O'Hara, G., Turgeon, J. **Ciprofloxacin (Cipro) Decreases Mexiletine (Mex) Clearance in Smokers and Non-Smokers.** Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1995;57:210.
86. Abolfathi, Z., Pakdel, H., Beaune, P., Turgeon, J. **CYP1A2 is the Major Enzyme Involved in the N-Oxidation of Mexiletine.** Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1995;57:216.
87. Khalifa, M., Daleau, P., Turgeon, J. **The Histamine H1-Receptor Antagonist Diphenhydramine Blocks the Delayed Rectifier Potassium Current.** 16th Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology. PACE, 1995;18:936.
88. Turgeon, J., Drolet, B., Vincent, F. **Cimetidine Modulates Action Potential Lengthening Effects of N-Acetylprocainamide.** Association of Faculties of Pharmacy of Canada Meeting. Montréal, May 1995.
89. Khallifa, M., Daleau, P., Turgeon, J. **Diphenhydramine Blocks the Delayed Rectifier Potassium Current in Guinea Pig Ventricular Myocytes.** Association of Faculties of Pharmacy of Canada Meeting. Montréal, May 1995.
90. Labbé, L., Lefez, C., Gilbert, M., O'Hara, G., Turgeon, J. **Mexiletine Oral Clearance is Decreased by Ciprofloxacin.** Association of Faculties of Pharmacy of Canada Meeting. Montréal, May 1995.
91. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **Sertraline and Fluoxetine Pharmacokinetics in Poor and Extensive Metabolizers of Debrisoquine.** Association of Faculties of Pharmacy of Canada Meeting. Montréal, May 1995.

92. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **Sertraline and Fluoxetine Pharmacokinetic Disposition in Poor and Extensive Metabolizers of Debrisoquine.** American College of Clinical Pharmacy, Annual Meeting. Pharmacotherapy, 1995;15:391-392.
93. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **Genetic Determinant of Sertraline and Fluoxetine Disposition in 20 Healthy Volunteers.** Canadian Society of Clinical Investigation. Clin. Invest. Med., 1995;18:B15.
94. Hamelin, B.A., Robitaille, N.M., Bogaty, P., Falardeau, V., Genest, M., Asselin, M.J., Rail, J., Turgeon, J. **Prevalence of the ACE Genotypes among Young Quebec Women With and Without Myocardial Infarction.** American Heart Association Scientific Conference on Hormonal, Metabolic and Cellular Influences on Cardiovascular Disease in Women. San Diego, October 1995.
95. Bogaty, P., Robitaille, N.M. Labbé, L., Boyer, L., Harnois, J., Auger, D., Coulombe, D., Turgeon, J. **Genotype Distribution of the Angiotensin-Converting Enzyme Insertion/Deletion (I/D) Polymorphism in Unheralded Myocardial Infarction and Uncomplicated Chronic Stable Angina.** Canadian Cardiovascular Society. Can. J. Cardiol., 1995;11.
96. Lessard, E., Bélanger, P.M., Hamelin, B.A., Turgeon, J. **Disposition of Procainamide in Subjects with Low or High CYP2D6 Activity.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1996;59:152.
97. Hamelin, B.A., Gravel, A., Turgeon, J. **Classic Antihistamines Inhibit CYP2D6 *In Vitro*.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1996;59:172.
98. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **Role of CYP2D6 in the Demethylation of Fluoxetine *In Vivo*.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1996;59:137.
99. Lessard, E., Hamelin, B.A., Turgeon, J. **Involvement of CYP2D6 in the N-Oxidation of Procainamide.** Association of Faculties of Pharmacy of Canada Meeting. Calgary, May 1996.
100. Hamelin, B.A., Bouayad, A., Gravel, A., Turgeon, J. **Classic Antihistamines Inhibit CYP2D6 *In Vitro*.** Association of Faculties of Pharmacy of Canada Meeting. Calgary, May 1996.
101. Hamelin, B.A., Turgeon, J., Vallée, F., Bélanger, P.M., Paquet, F., LeBel, M. **The Disposition of Fluoxetine but not of Sertraline is Altered in Poor Metabolizers of Debrisoquine.** 19th Annual Meeting of the Canadian College of Neuropsychopharmacology. Toronto, June 1996.
102. Bouayad, A., Turgeon, J., Hamelin, B. **Les antihistaminiques classiques inhibent le CYP2D6 *in vitro*.** 38ième Réunion annuelle du Club de recherches Cliniques du Québec. Med. Sciences, 1996;12:19.
103. Lessard, E., Hamelin, B., Bélanger, P.M., Turgeon, J. **Formation de la N-hydroxyprocainamide par le CYP2D6.** 38ième Réunion annuelle du Club de recherches Cliniques du Québec. Med. Sciences, 1996;12:20.
104. Drolet, B., Vincent, F., Turgeon, J. **Effets de la thioridazine sur le courant de repolarisation cardiaque delayed rectifier (IK) du cobaye.** 38ième Réunion annuelle du Club de recherches Cliniques du Québec. Med. Sciences, 1996;12:46.

105. Khalifa, M., Drolet, B., Turgeon, J. **Effets de la venlafaxine sur le potentiel d'Action et sur les courants potassiques du cœur de cobaye.** 38ième Réunion annuelle du Club de recherches Cliniques du Québec. Med. Sciences, 1996;12:47.
106. Daleau, P., Turgeon, J. **Effect of Lisinopril on Intercellular Resistance Between Guinea Pig Ventricular Cells.** Canadian Cardiovascular Society. Can. J. Cardiol., 1996;12:.
107. Khalifa, M., Drolet, B., Hamelin, B.A., O'Hara, G., Philippon, F., Gilbert, M., Turgeon, J. **Modulation of Cardiac Repolarization by Venlafaxine.** Canadian Cardiovascular Society. Can. J. Cardiol., 1996;12:83E.
108. Lessard, E., Hamelin, B.A., Bélanger, P.M., Turgeon, J. **Genetically-Determined CYP2D6 Mediates the N-Oxidation of Procainamide.** Canadian Cardiovascular Society. Can. J. Cardiol., 1996;12: 88.
109. Drolet, B., Vincent, F., Turgeon, J. **Thioridazine Blocks the Rapid Component of the Delayed Rectifier K⁺ Current and Lengthens Repolarization of Guinea Pig Ventricular Myocytes.** Noble Symposium Banff, November 1997.
110. Bouayad, A., Desgagné, P., Jobin, J., Turgeon, J. **Pharmacodynamic Interaction of Diphenhydramine and Metoprolol.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1997;61:223.
111. Hamelin, B.A., Gauvin, C., Turgeon, J. **In Vitro Inhibition of CYP3A4 by Histamine H1 Receptor Antagonists.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1997;61:228.
112. Labbé, L., Hamelin, B.A., Fiset, C., Lefez, C., O'Hara, G., Gilbert, M., Turgeon, J. **Mexiletine as a Probe Drug to Determine CYP2D6 Phenotype.** American Society for Clinical Pharmacology and Therapeutics Meeting. Clin. Pharmacol. Ther., 1997;61:227.
113. Bogaty, P., Robitaille, N.M., Boyer, L., Auger, D., Solymoss, S., Turgeon, J. **Hemostatic and Inflammatory Parameters in Subjects with Previous Unheralded Myocardial Infarction Compared to Longstanding Uncomplicated Stable Angina.** The 4th International Conference on Preventive Cardiology. Can. J. Cardiol., 1997;13:308B.
114. Khalifa, M., Hamelin, B.A., Turgeon, J. **Diphenhydramine Blocks the Rapid Component of the Delayed Rectifier Potassium Current.** XIXth Congress of the European Society of Cardiology. Eur. Heart J., 1997;18:9.
115. Khalifa, M., Drolet, B., Hamelin, B.A., Turgeon, J. **Modulation of Cardiac Repolarization by Venlafaxine.** XIXth Congress of the European Society of Cardiology. Eur. Heart J., 1997;18:88.
116. Bogaty, P., Solymoss, S., Boyer, L., Auger, D., Simard, S., Rail J., Léveillé, J., Turgeon, J. **Hemostatic and Inflammation Profile and Angiotensin-Converting Enzyme (ACE) Genotype in Subjects with a History of Multiple Acute Coronary Events.** Canadian Cardiovascular Society. Can. J. Cardiol., 1997;13:107C.
117. Drolet, B., Khalifa, M., Hamelin, B.A., Turgeon, J. **Inhibition of the Delayed Rectifier K⁺ Current by Cisapride in Guinea Pig Ventricular Myocytes.** Canadian Cardiovascular Society. Can. J. Cardiol., 1997;17:A9.
118. Hamelin, B.A., Pham, D., Desgagnés, V., Rail, J., Bogaty, P., Morin, J., Turgeon, J. **CYP2D6 Ultrarapid Metabolism and Response to Metoprolol.** Annual meeting of the American College of Clinical Pharmacy. Pharmacotherapy, 1997;17:A9.

119. Hamelin, B.A., Dorson, P., Pabis, D., Still, D., Turgeon, J. **CYP2D6 Mutations and Therapeutic Outcome in Schizophrenic Patients.** Annual meeting of the American College of Clinical Pharmacy. Pharmacotherapy, 1997;17:A303.
120. Labbé, L., Malenfant, J., Desgagnés, V., Turgeon, J., Hamelin, B.A. **Effect of Gender and Menstrual Cycle on CYP2D6 Activity.** Annual meeting of the American College of Clinical Pharmacy. Pharmacotherapy, 1997;17:A245.
121. Khalifa, M., Daleau, P., Hamelin, B.A., Turgeon, J. **Effets de la venlafaxine sur le courant sodique du cœur de cobaye.** Club de recherches cliniques du Québec. Médecine Sciences, 1997;13:9.
122. Drolet, B., Khalifa, M., Hamelin, B.A., Turgeon, J. **Effets du cisapride sur le courant de repolarisation cardiaque delayed rectifier (IK) du cobaye.** Club de recherches cliniques du Québec. Médecine Sciences, 1997;13:17.
123. Labbé, L., Hamelin, B.A., Fiset, C., Lefez, C., O'Hara, G., Gilbert, M., Turgeon, J. **Détermination du phénotype du CYP2D6 par l'administration de la mexilétine.** Club de recherches cliniques du Québec. Médecine Sciences, 1997;13:11.
124. Lessard, É., Bélanger, P.M., Turgeon, J. **Implication du CYP2D6 dans la formation de la N-hydroxyprocainamide in vitro dans les microsomes hépatiques humains.** Club de recherches cliniques du Québec. Médecine Sciences, 1997;13:22.
125. Turgeon, J., Asselin, M.J. **Utilisation d'une banque de tissus humains en maladies cardiovasculaires: Projet GÉNÉ-T-ICQ. Amélioration de l'index thérapeutique, des approches pharmacologiques et de l'évaluation pronostique ou diagnostique.** Club de recherches cliniques du Québec. Médecine Sciences, 1997;13:6.
126. Drolet, B., Khalifa, M., Hamelin, B.A., Turgeon, J. **Inhibition of the Delayed Rectifier K⁺ Current by Cisapride in Guinea Pig Ventricular Myocytes.** Canadian Cardiovascular Society. Can. J. Cardiol., 1997;13: 78C.
127. Bouayad, A., Desgagnés, P., Jobin, J., Poirier, P., Turgeon, J., Hamelin, B.A. **Diphenhydramine Alters Hemodynamic Effects of Metoprolol in Man.** Canadian Cardiovascular Society. Can. J. Cardiol., 1997;13: 81C.
128. Bogaty, P., Solymoss, S., Boyer, L., Auger, D., Simard, S., Rail, J., Léveillé, J., Turgeon, J. **Hemostatic and Inflammation Profile and Angiotensin Converting Enzyme (ACE) Genotype in Subjects with a History of Multiple Acute Coronary Events.** Canadian Cardiovascular Society. Can. J. Cardiol., 1997;13: 106C.
129. Ezzine, S., Pilote, S., Poirier, P., Turgeon, J., Hamelin, B.A. **Effects of Diphenhydramine on QT Interval in Healthy Volunteers with High and Low CYP2D6 Activity.** American College of Clinical Pharmacy, Palm Spring, CA. Pharmacotherapy, 1998.
130. Labbé, L., Hamelin, B.A., Champagne, J., Gilbert, M., O'Hara, G., Turgeon, J. **QRS Intervals during Combined Administration of Mexiletine and Propafenone.** American College of Clinical Pharmacy, Palm Spring, CA. Pharmacotherapy 1998.
131. Drolet, B., Khalifa, M., Hamelin, B.A., Daleau, P., Turgeon, J. **Inhibition of the Delayed Rectifier K⁺ Current by Cisapride in Guinea Pig Ventricular Myocytes.** World Congress of the International Society of Heart Research. J. Molec. Cell. Cardiol., 1998;30:A134.

132. Khalifa, M., Daleau, P., Drolet, B., Turgeon, J. **Block of Sodium Channels Underlies Unheralded Cardiac Toxicity Observed with the Antidepressant Agent Venlafaxine.** World Congress of the International Society of Heart Research. J. Molec. Cell. Cardiol., 1998;30:A136.
133. Dumesnil, J., Tremblay, A., Després, J.-P., Jobin, J., Gagnon, L., St-Pierre, S., Garneau, C., Montignac, M., Gilbert, M., Poirier, P., Turgeon, J. **Impact of a Shift from High-Carbohydrate to High-Protein Intake on Ad Libitum Energy Intake and Satiety in Overweight Individuals.** 8th International Congress on Obesity. International Journal of Obesity, 1998;22(3): S135.
134. Drolet, B., Zhang, S., Deschênes, J., Rail, J., Nadeau, S., Zhou, Z., January, C.T., Turgeon, J. **Effets du dropéridol sur la repolarisation cardiaque.** Club de recherches cliniques du Québec. Médecine Sciences, 1998;14:48.
135. Gauvin, C., Pilote, S., Turgeon, J., **Hamelin B.** **Inhibition du CYP2C9 par les antihistaminiques classiques.** Club de recherches cliniques du Québec. Médecine Sciences, 1998;14:55.
136. Labbé, L., Hamelin B. A., Champagne J., Gilbert M., O'Hara G., Turgeon, J. **Effets électrophysiologiques de mexilétine et du propafénone en coadministration.** Club de recherches cliniques du Québec. Médecine Sciences, 1998;14:56.
137. Khalifa, M., Daleau, P., Turgeon, J. **Mécanismes de blocage des canaux sodiques par la venlafaxine au niveau de myocytes ventriculaires du cobaye.** Club de recherches cliniques du Québec. Médecine Sciences, 1998;14:34.
138. Bogaty, P., Turgeon, J., Solymoss, S., Poirier, P., Boyer, L., Simard, S., Dagenais, GR. **Biological Profile in Subjects with Multiple Acute Coronary Events Compared to Longstanding Stable Angina.** Canadian Cardiovascular Society. Can. J. Cardiol., 1998;14: 116F.
139. Ezzine, S., Pilote, S., Poirier, P., Turgeon, J., Hamelin, B.A. **Diphenhydramine Metabolism and Cardiac Repolarization.** Canadian Cardiovascular Society. Can. J. Cardiol., 1998;14: 144F.
140. Lefebvre, J., Turgeon, J., Lacourcière, Y. **Relation entre le polymorphisme génétique de l'enzyme de conversion de l'angiotensine (ACE-I/D) et la toux induite par un traitement aux inhibiteurs de l'enzyme de conversion.** Société québécoise d'hypertension artérielle. Médecine Sciences, 1999;15:14
141. Hamelin, B., Méthot, J., Pilote, S., Poirier, P., Dumesnil, J., Turgeon, J. **Metoprolol/Diphenhydramine Interaction in Men with High and Low CYP2D6 Activity.** American Society for Clinical Pharmacology and Therapeutics, 1999;65:157.
142. Hamelin, B., Pilote, S., Turgeon, J. **Classic Antihistamines Inhibit Metoprolol-Hydroxylation In Vitro.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 1999;65:157.
143. Lessard, E., Yessine, M.A., Hamelin, B., Turgeon, J. **Venlafaxine-Diphenhydramine Interaction in Subjects with Extensive or Poor CYP2D6 Activity.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 1999;65:171.
144. Turgeon, J., Lessard, E., Yessine, M.A., Hamelin, B. **Pharmacokinetics of Venlafaxine in Subjects with Extensive or Poor CYP2D6 Activity.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 1999;65:171.

145. Lessard, E., Bélanger, P.M., Turgeon, J. **Urinary Excretion of Nitroprocainamide in Subjects with Low or High CYP2D6 Activity.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 1999;65:178.
146. Drolet, B., Zhang, S., Deschênes, D., Nadeau, S., Rail, J., Zhou, Z., January, C.T., Turgeon, J. **Effects of Droperidol on Cardiac Repolarization.** North American Society of Pacing and Électrophysiology. PACE, 1999;22:859.
147. Drolet, B., Bolduc, P., Fortin, V., Émond, A., Turgeon, J. **Cardiac Électrophysiological Effects of Vitamin K1 (phytonadione).** North American Society of Pacing and Électrophysiology. PACE, 1999;22:759.
148. Geelen, P., O'Hara, G., Plante, S., Philippon, F., Gilbert, M., Turgeon, J. **d-Sotalol Prevents Ischemia-Induced Action Potential Shortening in a Pig Model of Reversible Myocardial Ischemia: A Possible Mechanism for Proarrhythmia with Class III Antiarrhythmic Agents.** North American Society of Pacing and Électrophysiology. PACE, 1999;22:760.
149. Geelen, P., Drolet, B., Lessard, E., Gilbert, P., O'Hara, G., Turgeon, J. **Concomitant Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current May Excessively Prolong Cardiac Repolarization.** North American Society of Pacing and Électrophysiology. PACE, 1999;22:759.
150. Geelen, P., Drolet, B., Rail, J., Emond, A., Fortin, V., O'Hara, G.E., Turgeon, J. **Lengthening of cardiac repolarization and block of the rapid component of the delayed rectifier potassium current by the phosphodiesterase V inhibitor sildenafil (Viagra®).** XXIst Congress of the European Society of Cardiology. Eur. Heart J., 1999;20: (Abstr suppl);373.
151. Geelen, P., Drolet, B., Lessard, E., Gilbert, P., O'Hara, G.E., Turgeon, J. **Electrophysiological Effects of Combined Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current: Potential for Excessive Prolongation of Cardiac Repolarization.** XXIst Congress of the European Society of Cardiology. Eur. Heart J., 1999;20: (Abstr suppl);569.
152. Drolet, B., Geelen, P., Rail, J., Émond, A., Fortin, V., O'Hara, G.E., Daleau, P., Turgeon, J. **Lengthening of Cardiac Repolarization and Block of the Rapid Component of the Delayed Rectifier K⁺ Current by the Phosphodiesterase V Inhibitor Sildenafil (Viagra®).** Annual Meeting, Association of Faculties of Pharmacy of Canada, Québec City, 1999.
153. Drolet, B., Geelen, P., Rail, J., Émond, A., Fortin, V., O'Hara, G.E., Daleau, P., Turgeon, J. **Lengthening of Cardiac Repolarization and Block of the Rapid Component of the Delayed Rectifier K⁺ Current by the Phosphodiesterase V Inhibitor Sildenafil (Viagra®).** Canadian Cardiovascular Society 52nd Annual Meeting. Can. J. Cardiol., 1999; 15:157D.
154. Drolet, B., Geelen, P., Rail, J., Emond, A., Fortin V., O'Hara, G.E. Daleau P., Turgeon, J. **Lengthening of Cardiac Repolarization and Block of the Rapid Component of the Delayed Rectifier K⁺ Current by the Phosphodiesterase V Inhibitor Sildenafil (Viagra®).** 52nd Annual Meeting of the Canadian Cardiovascular Society. Can. J. Cardiol., 1999;15: (Suppl D); 157D.

155. Geelen P, Drolet, B, Rail J., O'Hara, G.E., Turgeon, J. **Sildenafil (Viagra®) May Lengthen Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current.** 72nd Scientific Sessions of the American Heart Association. Circulation, 1999; 100:I-280.
156. Lamarre, P., Potvin, D., Turgeon, J., Ducharme, MP. **Pharmacodynamic Bioequivalence of Two Formulations of Albuterol: A Novel Population PK/PD Method Compared with the Finney and the Emax Dose-Scale Approaches.** AAPS.
157. Simard, C., Geelen, P., O'Hara, G.E., Turgeon J. **Pharmacokinetic Interaction Between Simvastatin and Cisapride.** Clin. Pharmacol. Ther., 2000;67:149.
158. Labbé, L., Hamelin, B.A., Champagne, J., O'Hara, G., Turgeon, J. **Propafenone decreases mexiletine clearance in subjects with extensive CYP2D6 activity.** American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 2000;67.
159. Labbé, L., Hamelin, B.A., Champagne, J., O'Hara, G., Turgeon, J. **Pharmacokinetic and Pharmacodynamic Interaction Between Propafenone and Mexiletine.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 2000;67.
160. Turgeon, J. **La pharmacogénétique dans le développement du médicament: les interactions médicamenteuses.** 68^e Congrès de l'ACFAS. Montréal.
161. Turgeon, J. **Cytochrome P450 Interactions and Drug Actions on the Cardiovascular Systems: Could We Better Handle the Beast.** 30th Gordon Research Conference on Drug Metabolism. Plymouth, New Hampshire.
162. Simard, C., O'Hara, G.E., Prévost, J., Guilbaud, R., Massé, R., Turgeon, J. **Effects of Simvastatin on the Pharmacokinetics of Cisapride.** Association of Faculties of Pharmacy of Canada, Annual Meeting 2000, Saskatoon, SK, Canada.
163. Simard, C., O'Hara, G.E., Prévost, J., Guilbaud, R., Massé, R., Turgeon, J. **Effects of Simvastatin on the Pharmacokinetics of Cisapride.** 4th Congress of the European Association for Clinical Pharmacology and Therapeutics, Florence, Italy. Br. J. Clin. Pharmacol., 2000:July;249.
164. Simard, C., O'Hara, G.E., Prévost, J., Guilbaud, R., Massé, R., Turgeon, J. **Interaction pharmacocinétique entre le cisapride et la simvastatine.** 42^e Réunion annuelle du Club de Recherches Cliniques du Québec, Bromont. Med. Sciences, 2000;16 :12.
165. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Turgeon, J. **Le dompéridone ne semble pas plus sécuritaire que le cisapride pour traiter les désordres gastro-intestinaux.** Med. Sciences, 2000;16 :36.
166. Lefebvre, J., Bachvarov, D.R., Poirier, L., Turgeon, J., Lacourcière, Y. **A Genetic Polymorphism of Bradykinin (B2) Receptors is Associated with Angiotensin Converting Enzyme (ACE) Inhibitor-Related Cough.** Canadian Cardiovascular Congress 2000, Vancouver. Can. J. Cardiol., 2000;16 :108F.
167. Lefebvre, J., Turgeon, J., Poirier, L., Lacourcière, Y. **Genetic Polymorphism of Angiotensin Converting Enzyme (ACE) in ABPM-Confirmed Hypertensives with or without Type 2 Diabetes.** Canadian Cardiovascular Congress 2000, Vancouver. Can. J. Cardiol., 2000;16 :108F.

168. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Turgeon, J. **Domperidone (Motilium) May not Be a Safer Alternative for Cisapride in GI Motility Disorders Treatment.** Canadian Cardiovascular Congress 2000, Vancouver. Can. J. Cardiol., 2000;16 :185F.
169. Simard, C., Potvin, D., Lavigne, J., Turgeon, J. **New Approaches for the Estimation of the Terminal Half-Life.** American Association of Pharmaceutical Scientists, Annual meeting and Exposition, Indianapolis. AAPS Pharm. Sci., 2000;4:2.
170. D'angelo, G., Potvin, D., Turgeon, J. **Carry-Over Effects in Bioequivalence Studies.** American Association of Pharmaceutical Scientists, Annual meeting and Exposition, Indianapolis. AAPS Pharm Sci., 2000.
171. Potvin, D., D'angelo, G., Turgeon, J., Morin, J., Lavigne, J., Ducharme, M.P. **Comparison of analysis of Covariance (Ancova) and Analysis of Variance (Anova) in Bioequivalence (BE) Assessment of Endogenous Compounds.** American Association of Pharmaceutical Scientists, Annual meeting and Exposition, Indianapolis. AAPS Pharm Sci., 2000.
172. Simard, C., O'Hara, G.E., Prévost, J., Guibaud, R., Massé, R., Turgeon, J. **Simvastatin acid (SVA) concentrations are decreased during coadministration of cisapride.** American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 2001;69.
173. Simard, C., O'Hara, G.E., Prévost, J., Guilbaud, R., Massé, R., Turgeon, J. **Les concentrations plasmatiques de la simvastatine acide (SVA) sont diminuées durant la coadministration du cisapride.** 43^e Réunion annuelle du Club de Recherches Cliniques du Québec, Mont Ste-Anne. Med Sciences 2001.
174. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Simard, C., Turgeon, J. **Effets du pimozide sur la repolarisation cardiaque.** 43^e Réunion annuelle du Club de Recherches Cliniques du Québec, Mont Ste-Anne. Med Sciences 2001.
175. Turgeon, J., Simard, C. **Métabolisme *in vitro* de la dompéridone.** 43^e Réunion annuelle du Club de Recherches Cliniques du Québec, Mont Ste-Anne. Med Sciences 2001.
176. Morin, N., Simard, C., Turgeon, J. **Distribution allélique du polymorphisme du gène *MDR-1* dans la population française québécoise.** 43^e Réunion annuelle du Club de Recherches Cliniques du Québec, Mont Ste-Anne. Med Sciences 2001.
177. Simard, C., Massé, R., Lessard, E., Morin, N., Turgeon, J. **Characterization of major CYP450 isozymes involved in the *in vitro* metabolism of domperidone.** American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 2002;71: P25.
178. Turgeon, J., Morin, N., Simard, C. **Allelic distribution of the human *MDR1* gene polymorphism in French canadian population.** American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 2002;71: P102.
179. Drolet, B., Yang, T., Daleau, P., Roden, D.M., Turgeon, J. **Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.** North American Society of Pacing and Electrophysiology. PACE 2002.
180. Michaud, V., Simard, C., Turgeon, J. **Utilisation du dompéridone comme marqueur de l'activité du CYP3A4 et du CYP3A5.** 44^{ième} Réunion annuelle du Club de recherches cliniques du Québec, Mont St-Sauveur. Med Sciences 2002;18(2):28.

181. Morissette, P., Morin, N., Turgeon, J. **Detection de la glycoprotéine-P dans le myocarde de rat, de cobaye et d'humain.** 44^{ième} Réunion annuelle du Club de recherches cliniques du Québec, Mont St-Sauveur. Med Sciences 2002.
182. Morin, N., Turgeon, J. **Étude du polymorphisme génétique du cytochrome P-450 2C9 (CYP2C9) dans la population française québécoise.** 44^{ième} Réunion annuelle du Club de recherches cliniques du Québec, Mont St-Sauveur. Med Sciences 2002.
183. Michaud, V., Simard, C., Morin, N., Turgeon, J. **Domperidone as a substrate marker drug for CYP3A4 and CYP3A5.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmed. Ther 2003;73(2):47.
184. Morissette, P., Morin, N., Turgeon, J. **Modulatory role of P-Glycoprotein on the cardiac electrophysiological effects of an I_{Kr} blocker.** Association of Faculties of Pharmacy of Canada. Montréal, 2003.
185. Michaud, V., Simard, C., Massé, R., Turgeon, J. **Domperidone as a substrate marker drug for CYP3A4 and CYP3A5.** Association des facultés de pharmacie du Canada. Montréal, 2003.
186. Michaud, V., Simard, C., Massé, R., Turgeon, J. **A search for a substrate marker drug for CYP3A4 : domperidone.** Canadian Society of Clinical Pharmacology. Ottawa, 2003. Can. J. Pharmacol. 2003;10:152.
187. Morissette, P., Turgeon, J. **Olanzapine (Zyprexa®) prolongs cardiac repolarization.** Canadian Society of Clinical Pharmacology. Ottawa, 2003. Can. J. Clin. Pharmacol. 2003;10:145.
188. Morissette, P., Morin, N., Turgeon, J. **Cardiac electrophysiological effects of an I_{Kr} blocker are influenced by P-glycoprotein modulation.** Canadian Society of Clinical Pharmacology. Ottawa. 2003. Can. J. Pharmacol. 2003;10:153.
189. Morissette, P., Turgeon, J. **L'olanzapine (Zyprexa®) prolonge la repolarisation cardiaque.** 43^e Réunion annuelle du Club de recherches cliniques du Québec. Médecine Science 2003;19(2).
190. Michaud, V., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'Hara, G., Gossard, D., Champagne, M., Vanier, M.C., Turgeon, J. **Génotype ou phénotype? Leur rôle dans l'individualisation de traitement pour des agents cardiovasculaires.** 45^e Réunion annuelle du Club de recherches cliniques du Québec. Médecine Science 2003;19(2) :18.
191. Michaud, V., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'hara, G., Gossard, D., Champagne, M., Vanier, M.C., Turgeon, J. **Genotype or phenotype? Role of these strategies for individualized therapy for cardiovascular drugs in patients.** Canadian Cardiovascular Society. Toronto, 2003. Can J Cardiol 2003;19(Suppl A):171-2.
192. Michaud, V., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'hara, G., Gossard, D., Champagne, M., Vanier, M.C., Turgeon, J. **Comparison of genotypic and phenotypic strategies for individualized therapy with the narrow therapeutic drug warfarin.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2004;75(2):60.

193. Morissette, P., Morin, N., Turgeon, J. **ATP binding cassette membrane transporters as a key determinant for sex-related differences in drug-induced long QT-syndrome.** 25th Annual Scientific Sessions of NASPE, San Francisco, CA. Heart Rhythm; 2004;1:S93.
194. Michaud, V., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'hara, G., Gossard, D., Champagne, M., Vanier, M.C., Turgeon, J. **Phenotype strategies, a better approach for individualized warfarin therapy.** Association of Faculty of Pharmacy of Canada Conference 2004. Vancouver, BC.
195. Morissette, P., Turgeon, J. **ABC transporters as a key determinant for sex-related differences in drug-induced long QT-syndrome.** Association of Faculty of Pharmacy of Canada Conference 2004. Vancouver, BC.
196. Michaud, V., Harvey, M., Goodman, K., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'hara, G., Gossard, D., Champagne, M., Vanier, M.C., Ajami, A., Turgeon, J. **Warfarin as its own phenotypic probe drug : Nomogram for dose prediction in patients.** 8th World Congress on clinical Pharmacology and Therapeutics, Brisbane, Australia. Clin. Exper. Pharmacol. Phys. 2004;31:A133.
197. Hreiche, R., Morissette, P., Turgeon, J. **Assessment of gender differences under conditions of concomitant block of the rapid (I_{kr}) and slow (I_{ks}) components of the delayed rectifier potassium current in guinea pigs.** Canadian Cardiovascular Congress 2004. Can J Cardiol 2004;20(suppl A):517.
198. Morissette, P., Hreiche, R., Turgeon, J. **Gender-related differences in drug-induced Long QT syndrome : modulatory role of ABC transporters.** Canadian Cardiovascular Congress 2004. Can J Cardiol 2004;20(suppl A):519.
199. Hreiche, R., Morissette, P., Turgeon, J. **Impact des transporteurs ABC sur la cardiotoxicité de la dompéridone.** Club de recherches cliniques du Québec. Médecine Sciences 2004;20:17.
200. Morissette, P., Hreiche, R., Turgeon, J. **Les transporteurs ABC un déterminant majeur des différences observées entre les sexes dans le syndrome du long QT médicamenteux.** 46^e Réunion annuelle du Club de recherches cliniques du Québec. Médecine Sciences 2004;20:17.
201. Couture, L., Nash, J., Turgeon, J. **Comparaison par autoradioluminographie quantitative (QWBA) de la distribution tissulaire du ³H-dompéridone chez des cobayes non prétraités et prétraités au vérapamil, un modulateur de la P-glycoprotéine.** 46^e Réunion annuelle du Club de recherches cliniques du Québec. Médecine Sciences 2004;20(suppl 2):18.
202. Michaud, V., Harvey, M., Goodman, K., Pastinen, T., Phillips, M.S., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'hara, G., Gossard, D., Champagne, M., Vanier, M.C., Ajami, A., Turgeon, J. **Polymorphismes du CYP2C9 et de VKOR dans l'établissement d'un nomogramme de traitement pour la warfarine.** Club de recherche cliniques du Québec. Médecine Sciences 2004;20:20.
203. Couture, L., Nguyen, L., Tao, L., Nash, J.A., Turgeon, J. **Distribution of ³H-domperidone, a P-glycoprotein (P-GP) substrate, in heart structures and whole-body tissues of MDRIA (-/-) mice.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2005;77(2):P46.

204. Michaud, V., Massé, R., Turgeon, J. **CYP2J2 metabolizes domperidone in Guinea pig hearts.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2005;77(2):P75.
205. de Denus, S., Zakrzewski-Jakubiak, M., Bélanger, F., Dubé, M.P., Whittom, L., Ducharme, A., Racine, N., Lavoie, J., Turgeon, J., White, M. **Angiotensinogen and bradykinin B2 receptor gene polymorphisms are associated with levels of C-reactive protein in patients with heart failure.** J Card Fail 2005;11(supp):S129.
206. Hreiche, R., Turgeon, J. **L'administration concomitante de deux bloqueurs d'I_{Kr} n'induit pas une potentialisation de la prolongation de la repolarisation cardiaque.** 47^{ième} rencontre annuelle du Club de recherches cliniques du Québec. Médecine Sciences 2005;21:15.
207. Couture, L., Nash, J., Nguyen, L., Turgeon, J. **Implication de la P-glycoprotéine (P-gp) dans la distribution tissulaire du ³H-domperidone au cœur et aux autres tissus par l'utilisation de souris knock-out *MDR1A/IB*(-/-).** 47^{ième} rencontre annuelle du Club de recherches cliniques du Québec. Médecine Sciences 2005;21(suppl 2):18.
208. Michaud, V., Moukassi, S.M., Labbé, L., Lefebvre, M., Bélanger, P.M., Gilbert, M., Grech-Bélanger, O., Turgeon, J. **Effet inhibiteur de la propafénone sur l'élimination de la caféine.** 47^{ième} rencontre annuelle du Club de recherches cliniques du Québec. Médecine Sciences 2005;21(suppl 2):33.
209. Couture, L. Nash, John A., Nguyen, L., Turgeon, J. **Gender Differences in Pharmacokinetics and Distribution of Radioactivity in the Heart and Whole-Body Tissues of Hartley Guinea Pigs Following a Single Intraperitoneal Injection of ³H-Domperidone, a P-Glycoprotein (P-gp) Substrate.** Drug Met Rev 2005;37(suppl 2):85.
210. Couture, L., Nash, John A., Nguyen, L. Tao, L., Turgeon, J. **Distribution and Metabolite Profiling of ³H-Domperidone, a P-Glycoprotein (P-gp) Substrate, in Heart and Whole-Body Tissues in Male *mdr1a* (-/-) and Wild-Type Mice Following in IV Injection.** Drug Met Rev 2005;37(suppl 2):109.
211. de Denus, S., Zakrzewski-Jakubiak M., Dubé, MP, Bélanger, F., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Turgeon, J., White, M. **Angiotensinogen and bradykinin B2 receptor gene polymorphisms are associated with levels of C-reactive protein in patients with heart failure.** Can J Cardiol. 2005; 21 (Suppl C): 96C.
212. de Denus, S., Zakrzewski-Jakubiak, M., Dubé, MP, Bélanger, F., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Touyz, RM, Turgeon, J., White, M. **Angiotensin II Type I receptor A1166C gene polymorphism predicts acute hemodynamic effects and long-term neurohormonal changes in patients with heart failure treated with candesartan.** Can J Cardiol 2005; 21 (Suppl C): 97C.
213. Couture, L., Nash, J.A., Nguyen, L., Turgeon, J. **Effects of verapamil pre-treatment on the distribution of a P-Glycoprotein substrate, ³H-domperidone, in heart and whole-body tissues of Hartley Guinea pigs.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2006;79(2):80.
214. Hreiche, R., Turgeon J. **Lengthening of cardiac repolarization during the sequential administration of two IKr blockers : order of administration as a major determinant.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2006;79(2) :29.

215. Hreiche, R., Turgeon J. **Evaluation of gender-related differences in the prolongation of action potential duration during concomitant block of I_{Kr} and I_{Ks}.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2006;79(2):37.
216. Zakrzewski-Jakubiak, M., de Denus, S., Dubé, MP, Bélanger, F., White, M., Turgeon J. **Genotype frequencies for ten polymorphisms of the renin-angiotensin-aldosterone system between healthy and heart failure patients in the French-Canadian population.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2006;79(2) :15.
217. Zakrzewski-Jakubiak, M., de Denus, S., Dubé, MP, Bélanger, F., White, M., Turgeon J. **Genotype frequencies for ten polymorphisms of the renin-angiotensin-aldosterone system between healthy French-Canadians and other ethnic groups.** American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther. 2006;79(2) :66.
218. Michaud, V., Mouksassi, M-S, Labbé, L., Bélanger, P-M, Lefebvre, M., Gilbert, M., Grech-Bélanger, O., Turgeon, J. **Effects of propafenone on the pharmacokinetics of caffeine.** American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):21.
219. Michaud, V., Massé, R., Turgeon, J. **Inhibitory potency of clarithromycin towards CYP3As.** American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006; 79(2):77.
220. Fenneteau, F., Couture, L., Nash, JA, Turgeon, J., F. Nekka. **Effects of P-glycoprotein (P-GP) inhibition on the distribution of domperidone to cardiac tissue : development of a physiologically based pharmacokinetic model in MDR1A/B(-/-) and wild type mice.** American Society for Clinical Pharmacology and Therapeutics 2006. Clin Pharmacol Ther 2006;79(2):49.
221. Santuré, M., Brisson, D., Tardif, J.C., Tremblay, G., Turgeon, J., Lamarche, B., Phillips, M. S., Gaudet, D. **Déterminants génétiques de la relation entre le contenu en triglycéride des particules HDL et l'intolérance aux statines.** Réseau de médecine génétique appliquée. La génétique humaine au Québec - Qui fait quoi? Journées Génétiques 2006, 1^{er} et 2 mai 2006.
222. Fenneteau, F, Couture, L., Turgeon, J., Nekka, F. **Développement d'un modèle pharmacocinétique à base physiologique : Mise en évidence du rôle des transporteurs membranaires dans la distribution de la dompéridone.** 74^e Congrès de l'ACFAS, Montréal.
223. Michaud, V., Turgeon, J. **Potentiel inhibiteur de la clarithromycine et CYP3As.** 48^{ième} rencontre annuelle du Club de Recherche Clinique du Québec, St-Alexis-des-Monts. Médecine Sciences, 2006, 22(2):139.
224. Couture, L., Nash, JA., J. Turgeon. **Effets de pré-traitements au vérapamil sur la distribution de radioactivité au cœur et autres tissus chez des cobayes administrés au ³H-domperidone, un substrat de la P-glycoprotéine.** 48^e Réunion annuelle du Club de Recherches Cliniques du Québec, St-Alexis-des-Monts. Medecine Sciences 2006;22(2):29.

225. Hreiche, R., Ricard, G., Turgeon, J., Drolet B. **Effets de la concentration de glucose sur la repolarisation et les courants repolarisants lors d'un bloc pharmacologique de IKr et/ou IKs dans un modele cellulaire et de cœur isolé.** 48^{ième} rencontre annuelle du Club de Recherche Clinique du Québec, St-Alexis-des-Monts. Médecine Sciences 2006;22(2):139.
226. Hreiche, R., Turgeon, J., Drolet, B. **Effects of glucose concentration on repolarization under conditions of drug-induced blockade of the rapid (IKr) and / or the slow (IKs) components of the delayed rectifier potassium current in guinea pigs.** Canadian Cardiovascular Society Congress. Can J Cardiol 2006;22(Suppl D):506.
227. Michaud, V., Harvey, M., Goodman, K., Phillips, M., Morin, N., Brouillette, D., Roy, D., Taillon, I., O'Hara, G., Gossard, D., Champagne, M., Vanier, MC, Labbé, L., Ajami, A., Turgeon, J. **Polymorphisms in VKOR and phenotype of CYP2C9 contribute to inter-individual variability of warfarine effects.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2006, 22(Suppl D):223.
228. Lordkipanidzé M., Pharand, C., Nguyen T.A., Palisaitis, D.A., Turgeon, J., Sia, Y.K., Schampaert, E., Diodati, J.G.. **Effect of different dosing regimens of clopidogrel given before elective percutaneous coronary intervention on platelet function.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2006;22(Suppl D):270.
229. Lordkipanidzé, M., Pharand, C., Nguyen, T.A., Palisaitis, D.A., Turgeon, J., Sia, Y.K., Schampaert, E., Diodati, J.G. **The degree of inhibition of platelet aggregation by clopidogrel: a comparison of five platelet function tests.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2006, 22(Suppl D):379.
230. Lordkipanidzé, M., Diodati, J.G., Palisaitis, D.A., Turgeon, J., Sia Y.K., Schampaert, E., Pharand, C.. **Aspirin resistance in stable coronary artery patients: Implication of oxidative stress.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2006;22(Suppl D):437.
231. Lordkipanidzé, M., Pharand, C., Palisaitis, D.A., Turgeon, J., Sia Y.K., Schampaert, E., Diodati, J.G. **Low aspirin resistance prevalence in stable coronary artery patients as measured by arachidonic acid-stimulated optical aggregometry: A comparison with six major platelet function tests.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2006;22(Suppl D):704.
232. Couture, L., Nash, J.A., Nguyen, L., Turgeon, J. **Effects of verapamil pre-treatments on the distribution of radioactivity in heart and whole-body tissues of Hartley guinea pigs administered with ³H-domperidone, a P-glycoprotein substrate.** International Society for the Study of Xenobiotics (ISSX), Drug Met. Rev. 2006;30(Suppl 2):246.
233. Lordkipanidzé, M., Pharand, C., Diodati, J.G., Nguyen, T.A., Palisaitis, D.A., Bélanger, F., Sia, Y.K., Schampaert, E., Turgeon, J. **Evaluation of the effect of the H2 haplotype and CYP3A5 polymorphisms on the antiplatelet response to clopidogrel given before elective percutaneous coronary intervention.** American Society of Human Genetics, New Orleans, 2006:1967/A.
234. Lordkipanidzé, M., Pharand, C., Diodati, J.G., Palisaitis, D.A., Bélanger, F., Sia, Y.K., Schampaert, E., Turgeon, J. **Evaluation of the effect of the H2 haplotype and CYP3A5 polymorphisms on the antiplatelet response to clopidogrel given before elective percutaneous coronary intervention.** American Society of Human Genetics, New Orleans, 2006:1966/C.

235. Hreiche, R., Ricard, G., Turgeon, J., Drolet, B. **Modulatory effects of glucose concentration on cardiac repolarization under conditions of drug-induced blockade of I_{KR} and/or I_{KS} currents in guinea pigs.** American Society for Clinical Pharmacology and Therapeutics 2007. Clin Pharmacol Ther 2007;81(1):48.
236. Hreiche, R., Brice, F., Leoni, A., Yahi, H., Charpentier, F., Escande, D., Turgeon, J. **Gender differences in the electrophysiological effects of an I_{KR} blocker in a knockout mice model of efflux transporters.** American Society for clinical Pharmacology and Therapeutics 2007. Clin Pharmacol Ther 2007;81(1):49.
237. Couture, L. Nash, J.a., Nguyen, L., Turgeon, J. **Effects of verpamil pre-treatments on the distribution of 3H -domperidone, a P-glycoprotein substrate, in the heart and other tissues of male and female Hartley guinea pigs.** American Society for Clinical Pharmacology and therapeutics 2007. Clin Pharmacol Ther 2007;81(1):91.
238. Michaud, V., Harvey, M., Goodman, K., Morin, N., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, L., O'Hara, G., Gossard, D., Champagne, M., Rosati, S., Simard, M., Vanier, M., Phillips, M., Ajami, A., Turgeon, J. **CYP2C9 phenotype and CYP2C9 and VKORC1 genotypes as modulatory factors of warfarin effects in Caucasian patients with multiple drug regimen.** American Society for Clinical Pharmacology and Therapeutics 2007. Clin Pharmacol Ther 2007;81(1):92.
239. Lordkipanidzé, M., Pharand, C., Diodati, J.G., Palisaitis, D.A., Bélanger, F., Sia, Y.K., Schampaert, E., Turgeon, J. **Evaluation of the effect of the $PI^{A1/A2}$ dimorphism, of the $P2Y_1$ receptor gene 1622A/G mutation and of the COX-1 gene 22C/T mutation on platelet response to aspirin.** American Heart Association meeting, Chicago, IL, April 18-20, 2007.
240. Pharand, C., Lordkipanidzé, M., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati, J.G. **Aspirin resistance in stable coronary artery disease patients is associated with increased platelet turnover, but not oxidative stress.** Arteriosclerosis, Thrombosis and Vascular Biology Meeting, Chicago, IL, April 18-20, 2007.
241. Pharand, C., Lordkipanidzé, M., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati, J.G. **Lack of agreement between six major platelet function assays commonly used to assess the prevalence of aspirin resistance in stable coronary artery disease patients.** Arteriosclerosis, Thrombosis and Vascular Biology Meeting, Chicago, IL, April 18-20, 2007.
242. Pharand, C., Lordkipanidzé, M., Nguyen, T.A., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati, J.G. **Assays evaluating platelet inhibition provided by clopidogrel yield significantly different results and correlate poorly among themselves.** Arteriosclerosis, Thrombosis and Vascular Biology Meeting, Chicago, IL, April 18-20, 2007.
243. Pharand, C., Nguyen, T.A., Lordkipanidzé, M., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati JG. **Prolonged prophylactic administration of high-dose clopidogrel before elective percutaneous coronary intervention is more effective than the standard 300 mg bolus in inhibiting platelet aggregation.** Arteriosclerosis, Thrombosis and Vascular Biology Meeting, Chicago, IL, April 18-20, 2007.

244. Pharand, C., Nguyen, T.A., Lordkipanidzé, M., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati, J.G. **Effect of four different clopidogrel doses given before pci on platelet function.** 7th Spring Conference on Clinical Pharmacy, Edinburgh, UK, May 16-19, 2007.
245. Pharand, C., Lordkipanidzé, M., Palisaitis, D.A., Turgeon, J., Schampaert, E., Diodati JG. **Oxidative stress does not contribute to aspirin resistance in coronary disease patients.** 7th Spring Conference on Clinical Pharmacy, Edinburgh, UK, May 16-19, 2007.
246. Hreiche, R., Michaud, V., Simard, C., Turgeon, J., Drolet, B. **L'effet du dofétilide sur la repolarisation cardiaque est modulé par la concentration de glucose et par la diète riche en sucrose.** 49^e rencontre annuelle du Club de Recherche clinique du Québec, Mont-Tremblant, Médecine Sciences 2007;23(2):1.
247. Michaud, V., Dumas, M.C., Turgeon, J. **Le coeur, un organe doué d'activité métabolique envers le verapamil.** 49^e rencontre annuelle du Club de Recherche Clinique du Québec, Mont-Tremblant, Médecine Sciences 2007;23(2):42.
248. Michaud, V., Pronovost, B., Bouchard, P., Alain, K., Bilodeau, S., Roy, D.C., Busque, L., Vadenais, B., Turgeon, J. **Impact du polymorphisme de la GST-A1 sur le métabolisme du Busulfan administré par voie orale lors d'une pré-greffe de la moelle osseuse.** 49^e rencontre annuelle du Club de Recherche Clinique du Québec, Mont-Tremblant, Médecine Sciences 2007;23(2):43.
249. Caillier, B., Pilote, S., Ménard-Desrosiers, V., Hreiche, R., Turgeon, J., Daleau, P., Simard, C., Drolet, B. **La pro-arythmie cardiaque associée au bupropion (Wellbutrin Zyban) : un profil électrophysiologique cardiaque unique.** 49^e rencontre annuelle du Club de Recherche clinique du Québec, Mont-Tremblant, Médecine Sciences 2007;23(2):114.
250. De Denus, S., Gaudreault, N., Turgeon, J., White, M., Phillips, M.S. **Development of a focussed pharmacogenomics panel to predict the effects of rennin-angiotensin-aldosterone system inhibitors in patients with heart failure.** Canadian Cardiovascular Society Congress. Can J Cardiol 2007;23(C):463.
251. Hreiche, R., Michaud, V., Simard, C., Turgeon, J., Drolet, B. **Effects of glucose concentration on repolarization under conditions of drug-induced of I_{Kr} in guinea pigs fed with high sucrose diet.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2007, 23(C):803.
252. Caillier, B., Pilote, S., Ménard-Desrosiers, V., Hreiche, R., Turgeon, J., Daleau, P., Simard, C., Drolet, B. **Proarrhythmia with bupropion: A unique cardiac electrophysiological profile.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2007, 23(C):740.
253. Rinfret, S., Lussier, M.T., Duhamel, F., Cossette, S., Lalonde, L., Pierce, A., Tremblay, M.C., Guertin, J., Le Lorier, J., Turgeon, J., Hamet, P. **The impact of multidisciplinary, information technology supported program on blood pressure control in primary care (The Loyal Study).** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2007, 23(C):1002.
254. Dobie, M., Fournier, A., Masse, A., Turgeon, J., Pharand, C. **Analysis of QTC interval in children and adolescents treated with atypical antipsychotic.** Canadian Cardiovascular Society Congress. Can. J. Cardiol. 2007, 23(Suppl C):123.

255. Dobie, M., Fournier, A., Masse, A., Turgeon, J., Pharand, C. **Effect of atypical antipsychotic agents on QTc interval in pediatric patients.** Heart Rhythm 2007;4:S259.
256. Michaud, V., Dumas, M.C., Hreiche, R., Turgeon, J. **Metabolism of verapamil in the heart.** The 8th international ISSX Meeting, Sendai, Japan, October 9-12, 2007.
257. Michaud, V., Pronovost, B., Bouchard, P., Alain, K., Bilodeau, S., Bélanger, F., Roy, D.C., Busque, L., Vadenais, B., Turgeon, J. **Role of the GST-A1 single nucleotide polymorphisms in the metabolism of busulfan administrated orally in patients undergoing bone marrow transplantation.** The 8th international ISSX Meeting, Sendai, Japan, October 9-12, 2007:P66.
258. Bouchard, P., Bilodeau, S., Alain, K., Vadenais, B., Franco, M., Busque, L., Roy, D.C., Michaud, V., Turgeon, J. **Impact of individual characteristics on oral Busulfan pharmacokinetics in adults patients undergoing hematopoietic stem-cell transplantation.** American Society of Hematology. Blood 2007;110:1993.
259. Bouchard, P., Bilodeau, S., Alain, K., Vadenais, B., Franco, M., Michaud, V., Turgeon, J. **Evaluation of limited sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PIII-07.
260. Tonietto, E., Cuerrier, S., Boyer, M., Letarte, N., Noël, C., Michaud, V., Turgeon, J. **Clinical impact of drug interactions with chemotherapy metabolized by CYP3As.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PII-39.
261. Michaud, V., Dumas, M.C., Turgeon, J. **CYP2C8 is involved in the metabolism of verapamil in human heart microsomes.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PI-85.
262. Michaud, V., Turgeon, J. **Assessment of metabolic-intermediate complex formation by clarithromycin (CLAR) using the CYP3A probe drug domperidone (DOM) and freshly isolated and grown human hepatocytes.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PI-84.
263. Michaud, V., Turgeon, J. **Determination of relative levels of human cardiac CYP450 isoforms in patients with heart failure.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PI-83.
264. Michaud, V., St-Onge, M., Sirham-Daneau, A., Turgeon, J. **Improved HPLC assay for quantitative analysis of oxycodone, oxymorphone and noroxycodone in human biological fluids.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PI-82.
265. Turgeon, J., Poirier-Larabie, S., Furtos, A., Laplante, D., Gaudet, M., Santuré, M., Phillips, M., Tardif, J.C. **Determination of plasma levels of rosuvastatin in patients presenting with drug-related myotoxicity.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PIII-82.
266. Ligeret, H., Bélanger, F., Dion, J.P., Phillips, M., Tardif, J.C., Turgeon, J. **Plasma membrane transports in human muscular cells and their potential role in statin-induced toxicity.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1): PIII-35.

267. Zakrzewski-Jakubiak, M., Hreiche, R., Yahi-Kerbane, H., Bélanger, F., de Denus, S., Turgeon, J. **The multidrug resistance protein 7 is physically linked to the rapidity activating delayed rectifier potassium ion channel (I_{Kr}) in human cardiac ventricles.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1): PI-05.
268. Plante, I., Hreiche, R., Bélanger, F., Turgeon, J. **P-glycoprotein (<i>MDR1</i>) expression modulates IC₅₀ of Domperidone for block of the rapid component of the delayed rectifier potassium current (I_{KR}) in a HEK293 cell line stably expressing Herg.** Clinical Pharmacology and Therapeutics 2008, 83(Supp 1):PIII-390.
269. Rinfret, S., Lussier, M-T., Peirce, T., Duhamel, F., Cossette, S., Lalonde, L., Tremblay, C., Ali, F., Guertin, M-C, LeLorier, J., Turgeon, J., Hamet, P. **The impact of a multidisciplinary, information technology supported program on blood pressure control in primary care.** Journal of Hypertension 2008, 26 (Supp 1).
270. Colucci, P., Turgeon, J., Ducharme, M. **How long should one sample for proper PK characterization on BA/BE studies ?** American Association of Pharmaceutical Scientists, 2008, Atlanta, Georgia, USA.
271. de Denus, S., Zakrzewski-Jakubiak, M., Barhdadi, A., Leblanc, M.H., Racine, N., Bélanger, F., Carrier, M., Ducharme, A., Dubé, M.P., Turgeon, J., White, M. **CYP3A5*1/*3 genetic polymorphism is associated with post cardiac transplant renal dysfunction in patients treated with calcineurin inhibitors.** Canadian Cardiovascular Society Congress. Can J Cardiol 2008, 24(Suppl E):0316.
272. Lefebvre, J., Lacourcière, Y., Poirier, L., Turgeon, J. **Genetic variants of kinin receptors in hypertensive patients with ace-inhibitor related cough. A case-control study.** Canadian Cardiovascular Society Congress. Can J Cardiol 2008, 24(Suppl E):0224.
273. de Denus, S., Zakrzewski-Jakubiak, M., Barhdadi, A., Leblanc, M.H., Racine, N., Bélanger, F., Carrier, M., Ducharme, A., Dubé, M.P., Turgeon, J., White, M. **CYP3A5*1/*3 genetic polymorphism is associated with post cardiac transplant renal dysfunction in patients treated with calcineurin inhibitors.** Annual Scientific meeting of the Heart Failure Society of America, 2008, Toronto, Ontario, Canada.
274. Plante, I., Turgeon, J. . **Rosuvastatin blocks the I_{Kr} current at clinically relevant concentrations of the drug.** Clinical Pharmacol & Ther 2009, 85(Suppl 1):PII-59.
275. Michaud, V., Frappier, M., Bélanger, F., Turgeon, J. **Determination of mRNA levels of cardiac CYP450s involved in the metabolism of drugs from a large cohort of heart failure patients.** Clinical Pharmacol & Ther 2009, 85(Suppl 1):PI-13.
276. Colucci, P., Turgeon, J., Ducharme, M. **Bioequivalence potential of a new extended-release formulation determined by clinical trial simulations.** ACCP/ESCP International Congress on Clinical Pharmacy, Orlando, Florida, USA.
277. Michaud, V., Frappier, M., Turgeon, J. **Determination from a large cohort of heart failure patients of mRNA levels of cardiac CYP450s involved in the metabolism of drugs.** 11th European Regional ISSX Meeting, 2009, Lisbon, Portugal.
278. Sirhan-Daneau, A., Michaud, V., St-Onge, M., Turgeon, J. **Pharmacokinetics of oxycodone in extensive and poor metabolizers of CYP2D6 during co-treatment with placebo or quinidine.** 11th European Regional ISSX Meeting, 2009, Lisbon, Portugal.

279. Zakrzewski-Jakubiak, M., de Denus, S., White, M., Turgeon, J. **The GLY49Ser Beta1-adrenergic receptor and Del(322-325) Alpha-2c adrenergic receptor polymorphisms influence the hemodynamic response to carvedilol treatment in stable heart failure patients.** American College of Clinical Pharmacology, 2009, San Antonio, Texas.
280. Michaud, V., Dumas, M., Frappier, M., Turgeon, J. **Relationship between cardiac CYP450 mRNA levels and verapamil metabolism in human heart microsomes.** Canadian Cardiovascular Society Congress. Can J Cardiol 2009, 25(Suppl B):396.
281. Michaud, V., Frappier, M., Turgeon, J. **Cardiac CYP 450 mRNA levels in ischemic and non-ischemic hearts from a large cohort of patients with end-stage heart failure.** Canadian Cardiovascular Society Congress. Can J Cardiol 2009, 25(Suppl B):399.
282. Plante, I., Turgeon, J. **Rovuvastatin blocks the I_{Kr} current at clinically relevant concentrations of the drugs.** Canadian Cardiovascular Society Congress. Can J Cardiol 2009, 25(Suppl B):571.
283. Zakrzewski-Jakubiak, M., de Denus, S., White, M., Turgeon, J. **The GLY49ser Beta1-adrenergic receptor and DEL(322-325) Alpha-2c adrenergic receptor polymorphisms influence the hemodynamic response to carvedilol treatment in stable heart failure patients.** Canadian Cardiovascular Society Congress. Can J Cardiol 2009, 25(Suppl B):128.
284. Robidoux A, Rich E, Bureau NJ, Tremblay N, Turgeon J. **A prospective pilot study investigating the nature, the onset and the incidence of joint Pain in menopausal, breast cancer patients receiving aromatase inhibitor (AI) therapy.** Cancer Res 2009; 69(Suppl 24):4090.
285. Huguet, J., Michaud, V., Turgeon, J. **In vitro biotransformation of triazolam in human heart microsomes.** Clinical Pharmacol & Ther 2010, 87(Suppl 1):PII-20.
286. Turgeon, J., Bélanger, F., Tardif, J.C. **Modulation of mRNA levels of the membrane transporters OATP2B1 and ABCA1 by simvastatin lactone in human skeletal muscle cells.** Clinical Pharmacol & Ther 2010, 87(Suppl 1):PII-28.
287. Lamoureux, P., Turgeon, J., Tannenbaum, C. **Detection of drug-drug interactions in the hospitalized elderly: utility of a new cytochrome P450-based software.** Clinical Pharmacol & Ther 2010, 87(Suppl 1):PI-20.
288. Michaud, V., Skrobik, Y., Tarasevych, V., Colucci, P., Turgeon, J. **Population pharmacokinetics of fentanyl during continuous infusion in patients admitted to the intensive care unit.** Clinical Pharmacol & Ther 2010, 87(Suppl 1).
289. Zakrzewski-Jakubiak, M., de Denus, S., Leblanc, M.H., White, M., Turgeon, J. **The favourable hemodynamic response to carvedilol in heart failure patients might be compromised by two adrenergic receptor polymorphisms.** Clinical Pharmacol & Ther 2010, 87(Suppl 1).
290. Skrobik, Y., Michaud, V., Turgeon, J. **Delirium and coma in the ICU are associated with drug metabolism and transporter activity.** American Thoracic Society, 2010, New Orleans, Louisiana.

291. Michaud, V., Frappier, M., Champagne, M., Brouillette, D., Roy, D., Taillon, I., O'Hara, G., Gossard, D., Goodman, K., Phillips, M., Ajami, A., Turgeon, J. **Contribution of CYP4F2 genotypes to the variability of warfarin dose requirements in Caucasian patients.** ISSX Meeting, 2010, Indianapolis, USA.
292. Armstrong, C., Bélanger F., Turgeon, J. **Frequency of three transporters gene polymorphisms associated with statin transport in the Canadian Caucasian population.** Can J Clin Pharmacol 2010, 17(1).
293. Hugué, J., Michaud, V., Turgeon, J. **Biotransformation of triazolam in human liver and heart microsomes.** Can J Clin Pharmacol 2010, 17(1).
294. Michaud, V., Frappier, M., Champagne, M., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'Hara, G., Gossard, D., Goodman, K., Vanier, MC., Phillips, M., Ajami, A., Turgeon, J. **Assessment of the contribution of CYP4F2 genetic polymorphisms on warfarin dose requirements.** Can J Clin Pharmacol 2010, 17(1):204.
295. Sirhan-Daneau, A., Michaud, V., Manzini, C., Schwab, R., Demers, A., Roy, I., Lafrenchi, P., Chauny, J.M., St-Onge, M., Gaudette, F., Bélanger, F., Lavigne, G., Turgeon, J. **Role of CYP2D6 in the pharmacokinetics and pharmacodynamics of oxycodone in healthy volunteers during co-treatment with placebo of quinidine.** Can J Clin Pharmacol 2010, 17(1):211.
296. Plante, I., Frappier, M., Bélanger, F., Turgeon, J. **Block of the IKr current by the HMG-CoA reductase inhibitor rosuvastatin is modulated by BCRP, MDR1 and OATP2B1 membrane drug-transporter activities.** IUPHAR world congress 2010, Copenhagen, Denmark.
297. Michaud, V., Frappier, M., Champagne, M., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'Hara, G., Gossard, D., Goodman, K., Vanier, MC., Phillips, M., Ajami, A., Turgeon, J. **Effects of CYP4F2 genetic polymorphisms on warfarin dose requirements in Caucasian patients initiating therapy.** . IUPHAR world congress 2010, Copenhagen, Denmark.
298. Lachance, K., Barhdadi, A., Mongrain, I., Normand, V., Zakrzewski-Jakubiak, M., Bélanger, F., Leblanc, MH., Racine, N., Carrier, M., Ducharme, A., Turgeon, J., Dubé, MP., Phillips, M., White, M., de Denu, S. **TGFB1 is not associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients.** Canadian Cardiovascular Congress 2010, Montréal, Québec, Canada.
299. de Denu, S., Zakrzewski-Jakubiak, M., Barhdadi, A., Bélanger, F., Leblanc, M.H., Racine, N., Carrier, M., Ducharme, A., Dubé, M.P., Turgeon, J., White M. **Genetic and non genetic modulators of the cardiac expression of P-glycoprotein, an ABC efflux transporter.** Canadian Cardiovascular Congress 2010, Montréal, Québec, Canada.
300. Hugué, J., Michaud, V., Turgeon, J. **Biotransformation of triazolam in human liver and heart microsomes and human P450 supersomesTM 2J2.** International Congress of Pathophysiology 2010, Montréal, Québec, Canada.
301. Bélanger, F., Turgeon, J., Phillips, M., Tardif, J.C. **Modulation of mRNA of membrane transporters by simvastatin lactone in Human Skeletal Muscle Cells.** International Congress of Pathophysiology 2010, Montréal, Québec, Canada.

302. Armstrong, C., Bélanger, F., Balicki, D., Turgeon, J. **Expression of CYP450 mRNAs in various breast cancer cell lines.** International Congress of Pathophysiology 2010, Montreal, Quebec, Canada.
303. Michaud, V., Frappier, M., Champagne, M., Brouillette, D., Roy, D., Verret, L., Noël, N., Taillon, I., O'Hara, G., Gossard, D., Goodman, K., Vanier, M., Phillips, M., Ajami, A., Turgeon, J. **CYP4F2 genetic polymorphisms influence warfarin dose requirements in polymedicated patients initiating warfarin therapy.** Clinical Pharmacol & Ther 2010, 89(Suppl 1):17.
304. Huguet, J., Gaudette, F., Bélanger, F., Suzanne, D., Iglesias, L., Doucet, J., Nelson, M., Chiasson, JL., Hamet, P., Turgeon, J. **A drug-drug interaction study between rosuvastatin and pantoprazole after oral administration in healthy male subjects.** Clinical Pharmacol & Ther 2010, 89(Suppl 1):77.
305. Armstrong, C., Bélanger, F., Balicki, D., Turgeon, J. **Expression of CYP450 MRNAs in cancer stem cells isolated from various breast cancer cell lines.** Clinical Pharmacol & Ther 2010, 89(Suppl 1):79.
306. Armstrong, C., Bélanger, F., Gaudette, F., Balicki, D., Turgeon, J. **In Vitro metabolism study of specific CYP450 substrates in breast cancer cell lines.** Can Soc for Pharmaceutical Sc. 2011, p. 122.
307. Huguet, J., Gaudette, F., Bélanger, F., Dallaire, S., Iglesias, L., Doucet, J., Nelson, M., Chiasson, JL., Hamet, P., Turgeon, J. **A drug-drug interactions study between rosuvastatin and pantoprazole after oral administration in healthy male subjects.** Can Soc for Pharmaceutical Sc. 2011, p. 127.
308. Leung, Y., Bélanger, F., Armstrong, C., Turgeon, J. **Transport of Lactic Acid by mct1 and mct4 in cancer cell lines.** Can Soc for Pharmaceutical Sc. 2011, p. 129.
309. Lu, J., Armstrong, C., Bélanger, F., Gaudette, F., Balicki, D., Turgeon, J. **Development of an In Vitro system for the functional study of OATP1B1 transporter of statins.** Can Soc for Pharmaceutical Sc. 2011, p. 184.
310. Huguet J, Gaudette F, Chiasson J-L, Hamet P, Turgeon J. **A drug-drug interactions study between rosuvastatin and pantoprazole after oral administration in healthy male subjects.** J Clin Pharmacol 2011;51(9):1330.
311. Armstrong, C., Bélanger, F., Balicki, D. and Turgeon, J. **Expression of CYP450 mRNAs in cancer stem cells isolated from various breast cancer cell lines.** J Clin Pharmacol 2011;51(9):1356.
312. Lu, J., Gaudette, F., Bélanger, F. and Turgeon, J. **Development of an In Vitro system for the functional study of the OATP1A2 transporter in the uptake of statins.** J Clin Pharmacol 2011;51(9):1358.
313. Huguet, J., Gaudette, F., Bélanger, F., Dallaire, S., Chiasson, JL., Hamet, P. Turgeon, J. **Étude d'interactions médicamenteuses entre la rosuvastatine et le pantoprazole suite à une administration orale chez des sujets mâles en bonne santé.** CRCQ 2011, p. 48.
314. Lu, J., Bélanger, F., Gaudette, F., Turgeon, J. **Développement d'un système In Vitro pour étude fonctionnelle des transporteurs de statines OATP.** CRCQ 2011, p.75.

315. Armstrong, C., Bélanger, F., Balicki, D., Turgeon, J. **L'expression d'ARNm du cytochrome P450 dans les cellules cancéreuses souches cancéreuses isolées de diverses lignées cellulaires du cancer du sein.** CRCQ 2011, p. 77.
316. Leung, YH., Bélanger, F., Armstrong, C., Lu, J., Turgeon, J. **Transport d'acide lactique par MCT1 et MCT4 dans des lignées cellulaires cancéreuses.** CRCQ 2011, p.151.
317. de Denus, S., Phillips, MS., Dubé, MP., Turgeon, J., Lavoie J., Guertin, MC., O'Meara, E., Ducharme, A., Racine, N., Tardif JC., Rouleau JL., White, M. **Baseline characteristics, hemodynamic, clinical and biochemical response to candesartan in a prospective, multicenter pharmacogenomic study of heart failure patients already receiving an ace inhibitor.** Can J of Cardiol 2011, 27(5):247.
318. Huguet, J., Chéhadé, E., Michaud, V., Gaudette, F. Turgeon, J. **Functional activity of human heart microsomes expressing CYP2E1.** Clinical Pharmacol & Ther 2012, 91(Suppl 1):18.
319. Huguet, J., Michaud, V., Gaudette, F., Turgeon, J. **CYP450 functional activities in human heart microsomes.** Clinical Pharmacol & Ther 2012, 91(Suppl 1):19.
320. Armstrong, C., Huguet, J., Gaudette, F., Belanger, F., Balicki, D., Turgeon, J. **InVitro metabolism study of evastine and 7-ethoxyresorufin in breast cancer cell lines.** Clinical Pharmacol & Ther 2012, 91(Suppl 1):20.
321. Leung, Y., Belanger, F., Armstrong, C., Lu, J., Turgeon, J. **Drug-transporter interactions: inhibition of mct1 and mct4 by statins.** Clinical Pharmacol & Ther 2012, 91(Suppl 1):60.
322. Lu, J. Gaudette, F., Leung Y., Turgeon, J. **Drug-drug interactions between Rosuvastatin and β -blockers through the OATP1A2 transporter.** Clinical Pharmacol & Ther 2012, 91(Suppl 1):60.
323. Xang, J., Moya Guilarte, L.G., Armstrong, C., Turgeon, J. **Caractérisation d'un nouveau rôle des CYP450s dans la physiopathologie des cellules cancéreuses de l'endomètre.** CRCQ 2012, p. 68.
324. Leung, Y., Lu, J., Bélanger, F., Turgeon, J., Michaud, V. **Interactions médicamenteuses : inhibition des MCT1 et MCT4 par les statines et autres médicaments acides.** CRCQ 2012, p. 136.
325. Lu, J., Leung, Y., Gaudette, F., Turgeon, J. **Interactions médicamenteuses entre la rosuvastatine et des béta-bloqueurs par le transporteur OATP1A2.** CRCQ 2012, p.137.
326. Huguet, J., Gaudette, F., Michaud, V. Turgeon J. **Évaluation de l'activité fonctionnelle des CYP 450s dans les microsomes de cœurs humains.** CRCQ 2012, p.138.
327. Huguet, J., Gaudette, F., Michaud, V., Turgeon, J. **A probe drug cocktail to study CYP2C8, 1A1 and 2D6 in the human heart.** Clinical Pharmacol & Ther 2013, 93 (Suppl 1):60.
328. Leung, Y., Lu, J., Bélanger F., Turgeon, J., Michaud, V. **Drug-transporter interactions : inhibition of MCT1 and MCT4 by statins and other acidic drugs,** Clinical Pharmacol & Ther 2013, 93(Suppl 1):60.

329. Lu, J., Guilarte Moya, L.G., Leung, Y., Gaudette, F., Turgeon, J. **Tricyclic drugs inhibit the uptake of rosuvastatin through the OATP1A2 transporter**, Clinical Pharmacol & Ther 2013, 93(Suppl 1):30.
330. Yang, X., Gaudette, F., Guilarte, L.G., Armstrong, C., Turgeon, J. **mRNA levels of cytochrome P450s in endometrial cancer cells**. Clinical Pharmacol & Ther 2013, 93(Suppl 1):98.
331. Lu, J., Guilarte Moya, L.G., Leung, Y., Gaudette, F., Turgeon, J. **Tricyclic compounds inhibit the OATP1A2 transporter**, CSPT 2013, Boston, MA.
332. Huguet J., Gaudette F., Michaud V., Turgeon J. **Functional activity in human heart expressing CYP1A1**, CSPT 2013, Boston, MA.
333. Leung, Y., Lu, J., Papillon, M., Bélanger, F., Turgeon, J., Michaud, V. **The role of MCT1 and MCT4 in drug-induced muscle disorders**, CSPT 2013, Boston, MA.
334. Martel, D., Sheehan, N.L., Tremblay, C.L., Turgeon, J., Tseng, A., Phaneuf, D., Noël, G.E., Thibeault, D., Labbé, I. **Pharmacokinetic interaction of the direct acting antiviral agent beceprevir with maraviroc in healthy volunteers**, 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands.
335. Leung, Y., Lu, J., Bélanger, F., Turgeon, J., Michaud, V. **Rôle des transporteurs MCT1 et MCT4 dans les désordres musculaires induits par les statines**, CRCQ 2013, p. 203.
336. Leung, Y., Papillon, M., Turgeon, J., Michaud, V. **Statin-specific transport by MCT1 and MCT4**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):29.
337. Huguet, J., Gaudette, F., Bélanger, F., Michaud, V., Turgeon, J. **Intersubject variability CYP212 activity in human heart microsomes**. Clinical Pharmacol & Ther 2014, 95(Suppl 1):30.
338. Huguet, J., Sharma, S., Gaudette, F., Bélanger, F., Fulton, S., Turgeon, J., Michaud, V. **CYP450 mediated metabolism in extra-hepatic tissues**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):30.
339. Lu, J., Guilarte Moya, L., Leung, Y., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Inhibition of the OATP1A2 transporter by tricyclic compounds**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):70.
340. Gravel, S., Huguet, J., Rousseau, E., Gaudette, F., Turgeon, J., Michaud, V. **CYP450 mediated drug metabolism in human lung tissue**. 19th North American ISSX meeting, San Francisco, October 2014.
341. Lu, J., Grangeon, A., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on almotriptan transport through OATP1A2**. 19th North American ISSX meeting, San Francisco, October 2014.
342. Huguet, J., Bélanger, F., Michaud, V., Turgeon, J. **Impact of CYP2J2*7 on drug metabolism in the human heart**. 19th North American ISSX meeting, San Francisco, October 2014.
343. Pelletier, R., Gravel, S., Huguet, J., Turgeon, J., Michaud, V. **Metabolism of olanzapine in human heart microsomes**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-018.

344. Gravel, S., Huguet, J., Gaudette, F., Turgeon, J., Michaud, V. **Iloperidone metabolism in human hearts**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-015.
345. Ghazal, N., Yeung, Y., Ngan, Z., Wang, H., El-Sakkary, M., Bélanger, F., Sheehan, N., Lebouché, B., Turgeon, J., Labbé, L., Michaud, V. **Comparison of drug-transporter mRNA expression levels in PBMC from HIV-infected patients with and without diabetes**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-031.
346. Lu, J., Grangeon, A., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on naratriptan transport through OATP1A2**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-025
347. Leung, Y., Turgeon, J., Michaud, V. **Statin inhibition of lactic acid transport in human skeletal muscle**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, : PII-012.
348. Pilote, S., Kamaliza, J., Turgeon, J., Michaud, V., Simard, C., Drolet, B. **The effect of intracellular methadone on hERG current is modulated by the coexpression of the CYP450 isozyme 2B6**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-014
349. Maximos, S., Leung, Y., Gravel, S., Bélanger, F., Gaudette, F., Turgeon, J., Michaud, V. **Hepatic and extra-hepatic CYP450s activity modulation in C57BL/6 mice fed a high-fat diet**. 20th North American International Society of the Study of Xenobiotics, Orlando FL, 2015: P208.
350. Lu, J., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on zolmitriptan transport through OATP1A2**. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P250.
351. Grangeon, A., Gaudette, F., Turgeon, J., Michaud, V. **Highly sensitive LC-MS/MS methods for the in vivo assessment of human CYP450 activities using small doses of probe-drugs**. North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P3.
352. Gravel, S., Huguet, J., Gaudette, F., Turgeon, J., Michaud, V. **Iloperidone metabolism in human heart microsomal and cytosolic fractions**. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: PII-136.
353. Leung, Y., Turgeon, J., Michaud, V. **Inhibition of lactic acid efflux by atorvastatin in human skeletal muscle cells**. North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: P259.
354. Gravel, S., Grangeon, A., Gaudette, F., Chiasson, J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud, V. **Type 2 diabetes modulates CYP450 metabolic activities**. 10th MDRC annual meeting. Montreal, Quebec, 2016. Oral poster (ranked in the top 10%).
355. Gravel, S., Grangeon, A., Gaudette, F., Chiasson J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud, V. **Type 2 diabetes modulates CYP450 metabolic activities; an important factor of variability in drug response**. American Society for Pharmacology and Therapeutics meeting, San Diego 2016. Late-breaking abstract.

356. Steffen, L.E., Knowlton, C.H., Turgeon, J. **Development of a drug-specific Long QT-JT Index for prediction of drug-induced QT Prolongation.** American Heart Association Annual Meeting Scientific Sessions. Circulation 2016;134:A15939.
357. Steffen, L.E., Knowlton, C.H., Turgeon, J. **Risk Identification of drug-induced Long QT Syndrome using a Patient-Specific Long QT-JT Risk Score.** American Heart Association Annual Meeting Scientific Sessions. Circulation;134:A16114.
358. Gravel, S., Grangeon, A., Gaudette, F., Belanger, F., Chiasson, J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud V. **Effect du diabete de type 2 sur le metabolisme des medicaments par les Cytochromes P450.** Annual scientific meeting of Cardiometabolic Health, Diabetes and Obesity Research Network and COLoSUS Congress. Magog-Oford, Quebec, 2017. #51.
359. Cicali, B., Badea, G., Steffen, L., Bain, K.T., Schwartz, E., Knowlton, C.H., Turgeon J. **The application of a novel medication risk stratification tool to identify high risk patients within a large population.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S60.
360. Cicali, B., Badea, G., Bain, K.T., Knowlton, C.H., Turgeon J. **Visualization technique for FAERS-based adverse event prediction.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S25.
361. Steffen, L.E., Badea, G., Cicali, B., Knowlton, C.H., Turgeon, J. **Medication-Specific Long QT-JT Index And Patient-Specific Long QT-JT Score For Assessing Risk Of Torsade De Pointes: Validation In An Ambulatory Population.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S48
362. Schwartz, E.J., Patel, J., Patel, P., Shah, H., Issa, A.M., Turgeon, J., Knowlton, O.V., Knowlton, C.H., Bain, K.T. **Implementing an enhanced Standardized medication therapy management approach within a primary care setting.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S45.
363. Grangeon, A., Clermont, V., Barama, A., Gaudette, F., Turgeon, J., Michaud, V. **Simultaneous absolute protein quantification method of 14 CYP450s in human intestine by mass-spectrometry-based targeted proteomics.** American Society for Pharmacology and Therapeutics meeting. Clin Pharmacol Ther 2017;101:S66.
364. Leung, Y., Turgeon, J., Michaud, V. **Loratadine, a potent inhibitor of lactic acid transporters MCT1 and MCT4 in human skeletal muscle cells.** American Society for Pharmacology and Therapeutics meeting. American Society for Pharmacology and Therapeutics meeting. Clin Pharmacol Ther 2017;101:S35.
365. Gravel, S., Chiasson, J.L., Dallaire, S., Langelier, H., Grangeon, A., Gaudette, F., Belanger, F., Turgeon, J., Michaud, V. **Influence of type 2 diabetes on cytochromes P450 mediated drug metabolism.** American Society for Pharmacology and Therapeutics meeting. (within the top 20% of abstracts). Clin Pharmacol Ther 2017;101:S30
366. Gravel S, Panzini B, Chiasson JL, Gaudette F, Grangeon A, Turgeon J, Michaud V. **Effects of type 2 diabetes on duodenal CYP450 activities.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PT-011 & PWIII-004. (*Presidential Trainee Award*)

367. Michaud V, Cicali B, Verzicco J, Knowlton CH, Turgeon J. **Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs**. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-095.
368. Cicali B, Verzicco J, Knowlton CH, Turgeon J, Michaud V. **Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs**. American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-032.
369. Michaud V, Turgeon J. **Pain management pharmacotherapy in the context of polypharmacy and drug-drug interactions**. Global Pain Conference. Florence, Italy, August 2018.
370. Turgeon J, Michaud V. **Les tests pharmacogénomiques: le rôle des pharmaciens et des médecins**. International Congress on Personalized Health Care. September 2018.
371. Turgeon J, Michaud V. **The need for clinical decision support systems for the management of patients with polypharmacy**. International Congress on Personalized Health Care. September 2018.
372. Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J. **Impact of GSTA1 polymorphisms on the oral clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation**. International Congress of Personalized Health Care 2nd edition. Montreal, Canada, September 2018. Oral presentation (09/25/2018).
373. Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. **Influence of GSTA1 Polymorphisms On The Oral Clearance Of Busulfan Using Limited Sampling Methods In Adult Patients Undergoing Hematopoietic Stem Cell Transplantation**. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019. *Selected for the the Special Poster Session: Pharmacogenomics and for the Presidential Trainee Award*.
374. Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. **Use of 4 β -hydroxycholesterol plasma concentration as an endogenous biomarker of CYP3A activity: Clinical validation in patients with type 2 diabetes**. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019.
375. Michaud V, Lingineni K, Turgeon J, Schmidt S. **Physiologically-based pharmacokinetic (PBPK) clopidogrel and its active metabolite when administered alone or during concomitant administration with esomeprazole considering time-dependent inhibition**. Clin Pharmacol Ther 2020; 107, (S1) PIII-128.
376. Lingineni K, Turgeon J, Schmidt S, Michaud V. **PBPK modeling of clopidogrel and its active metabolite when administered alone or during concomitant administration with esomeprazole or ketoconazole**. American Society for Pharmacology and Clinical Therapeutics meeting, March 2020.
377. Long T, Cristofolletti R, Michaud V, Dow, P, Turgeon J, Schmidt S. **CYP2D6-Mediated Drug-Drug Interaction (DDI) between Tramadol, O-Desmethyltramadol and Quinidine via Allosteric Inhibition using Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation**, American Society for Pharmacology and Clinical Therapeutics meeting, March 2021.

378. Long T, Cristofolletti R, Michaud V, Dow, P, Turgeon J, Schmidt S. **Physiologically-based Pharmacokinetic (PBPK) Modeling to Assess CYP2D6-Mediated Drug-Drug Interaction (DDI) between Tramadol and Metoprolol due to Competitive Inhibition**, American Society for Pharmacology and Clinical Therapeutics meeting, March 2021.
379. Long T, Cristofolletti R, Turgeon J, Michaud V, Galiano L, Farhan N, Schmidt S. **Quantitative Translational Modeling to Assess the Impact of Cytochrome P450 2D6 Activity on Tramadol and O-Desmethyltramadol Exposure**, American Conference on Pharmacometrics, November 2020.
380. SanFillippo S, Michaud V, Wei S, Turgeon J, Brunetti L. **Classification and Assessment of Medication Risk in the Elderly (CARE)**. Poster presented at annual American Society of Health System Pharmacists Clinical Midyear Meeting; December 6-10, 2020 (RP-438).

Professional Manuscripts:

1. Turgeon, J. **Variabilité interindividuelle dans le traitement des arythmies cardiaques.** Le Clinicien, 1994.
2. Turgeon, J. **Critères d'équivalences entre les produits innovateurs et les génériques.** Le Point Médical, 1996, 2(12) :10-12.
3. Turgeon, J. **Pharmacothérapie de l'arythmie cardiaque.** Le Clinicien, 1996, mai:14-17.
4. Mancini, J., Anderson, T., Gotleib, A., Marquis, J.F., Turgeon, J. **The Emerging Role of ACE inhibitors in Coronary Artery Disease.** Jeux de diapositives et textes de commentaires. The Medicine Group, Mississauga, 1996.
5. Mancini, J., Anderson, T., Gotleib, A., Marquis, J.F., Turgeon, J. **Le rôle naissant des inhibiteurs de l'ACE dans la maladie coronarienne.** Jeux de diapositives et textes de commentaires. The Medicine Group, Mississauga, 1996.
6. Turgeon, J. **Considérations pharmacocinétiques et pharmacogénétiques dans le contrôle de la douleur.** Le Clinicien, 1997; mai: 7-9.
7. Turgeon, J. **Intersubject variability in the Pharmacokinetics of losartan.** Angiotensin II receptor blockade : physiological and clinical implications. Dhalla NS, Zahradka P, Dixon IMC and Beamish RE, eds. Kluwer Academic Publishers. Boston, 1998, 153-161.
8. Turgeon, J. **Le thérapeute généticien.** PharmActuel – La revue de la pratique pharmaceutique en établissement de santé au Québec 2002, (35):17-18.
9. Turgeon, J., V. Michaud. **Le cytochrome P450 et les interactions médicamenteuses.** L'actualité médicale 2002, (23):3-5.
10. Michaud, V., J. Turgeon. **Les cytochromes P450 et leur rôle clinique.** Le Médecin du Québec 2002, (37):73-84.
11. Michaud, V., J. Turgeon. **L'importance clinique des interactions médicamenteuses reliées aux isoenzymes du cytochrome P450 : de la fiction à la réalité.** PharmActuel – La revue de la pratique pharmaceutique en établissement de santé au Québec 2003, (36):88-96.
12. Michaud, V., J. Turgeon. **Cytochrome P450, drug interactions and the treatment of dementia.** *Geriatrics and Aging.* 2003, 6(2):22-7.
13. Hreiche, R., J. Turgeon. **Interactions médicamenteuses et risque de torsades de pointes.** Pharmactuel – La revue de la pratique pharmaceutique en établissement de santé au Québec, 2005, 38(3):134-9.
14. Zakrzewski-Jakubiak, M., Hreiche, R., J. Turgeon. **Abaissement intensif du cholestérol LDL par l'atorvastatine chez des patients atteints de maladie coronarienne stable : commentaires relatifs à l'étude TNT.** Pharmactuel – La revue de la pratique pharmaceutique en établissement de santé au Québec, 2005, 38(4) :190-9.
15. Michaud, V., Hreiche, R., Turgeon, J. **Les CYP450 et la gestion des interactions médicamenteuses dans la pratique quotidienne.** L'Actualité Pharmaceutique, 2006;1-8.
16. Turgeon, J., Michaud, V. **1, 2, 3 prescriptions, 4, 5, 6 interactions.** Le Médecin du Québec, 2008, 43(12):39-44.

17. Michaud, V., Turgeon, J. **La médecine personnalisée frappe à votre porte.** Le Médecin du Québec, 2008, 43(12):75-79.
18. Constance, C., Pollak, T., Turgeon, J. **Colloquium: emerging trends in the management of hypertension.** The Medical Post, educational supplement, May 2010.
19. Michaud, V., Turgeon, J. **Inhibiteurs de la pompe à protons, CYP2C19 et clopidrogel, où en sommes-nous ?** Pharmactuel – La revue de la pratique pharmaceutique en établissement de santé au Québec, 2010, 43(4) :222-223.
20. Michaud, V., Turgeon, J. **Les interactions médicamenteuses; fiction ou réalité,** Bulletin Santé de Croix Bleue, 2012.

Book Chapters:

1. De Champlain, J., Turgeon J. **HTA et cœur.** Hypertension artérielle 2002. Guide thérapeutique de la Société québécoise d'hypertension artérielle. 2^e édition. 2002. pp 151-165.
2. Turgeon, J., Dorian, P. **Principle of clinical pharmacology** , Electrophysiological Disorders of the Heart, 2004, Chapter 5, pp. 87-94.
3. De Champlain, J., Turgeon, J. **L'hypertension artérielle, la fréquence cardiaque et les arythmies cardiaques** dans Hypertension, Guide thérapeutique de la Société québécoise d'hypertension artérielle. 3^e édition, 2007, pp 175-179.
4. Hreiche, R., Michaud, V., Turgeon, J. **The role of ethnicity in managing cardiovascular patients.** Cardiovascular Genetics and Genomics, Roden D.M. editor. American Heart Association Monographs, 2008, Chapter 3, pp 33-47.
5. Turgeon, J., Dorian, P. **Principles of clinical pharmacology.** Electrophysiological Disorders of the Heart, second edition, 2011, Section II, Chapter 12.
6. Costi, P., Turgeon, J. **L'hypertension artérielle, la fréquence cardiaque et les arythmies.** Guide thérapeutique de la Société québécoise de l'hypertension, 4^e édition, 2012, Chapitre 18.

NIH Grants:

Hesperos, Inc and Tabula Rasa HealthCare Partnership

Human on a chip evaluation of drug-drug interactions associated with COVID-19 Therapeutics for at risk populations

PI: James Hickman

Collaborators: Jacques Turgeon, Veronique Michaud

Budget: \$500,000 to TRHC

Submitted, May 2020

Period-of-performance: June 15, 2020 - June 14, 2022

Hesperos, Inc and Tabula Rasa HealthCare Partnership

Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Cholinergic Drug Induced Dementia

PI: James Hickman, Jacques Turgeon

Collaborators: Michael Schur, Veronique Michaud

Budget: \$553,207 to TRHC

Awarded, August 2021

Period-of-performance August 15, 2021 – July 31, 2023

Hesperos, Inc and Tabula Rasa HealthCare Partnership

Impact of Low Level Chronic Systemic Inflammation on Alzheimer's Drug Disposition and Action

PI: James Hickman, Jacques Turgeon

Collaborators: Michael Schur, Veronique Michaud

Budget: \$550,000 to TRHC

Submitted, September 2020,

Period-of-performance April 1, 2021 - March 31, 2023

Submitted Patents:

1. Medication Regimens and Associated Methods (Previously Titled: Medication Risk Mitigation Matrix System and Method)
2. Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications
3. Population-Based Medication Risk Stratification and Personalized Medication Risk Score
4. System and Method of Processing Pharmaceutical Substance Data